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Developmental neurobehavioral outcomes attributed to exposure to chlorpyrifos (CPF)
obtained from epidemiologic and animal studies published before June 2010 were reviewed
for risk assessment purposes. For epidemiological studies, this review considered (1) over-
all strength of study design, (2) speciﬁcity of CPF exposure biomarkers, (3) potential for
bias, and (4) Hill guidelines for causal inference. In the case of animal studies, this review
focused on evaluating the consistency of outcomes for developmental neurobehavioral end-
points from in vivo mammalian studies that exposed dams and/or offspring to CPF prior
to weaning. Developmental neuropharmacologic and neuropathologic outcomes were also
evaluated. Experimental design and methods were examined as part of the weight of evi-
dence. There was insufﬁcient evidence that human developmental exposures to CPF produce
adverse neurobehavioral effects in infants and children across different cohort studies that
may be relevant to CPF exposure. In animals, few behavioral parameters were affected fol-
lowing gestational exposures to 1 mg/kg-d but were not consistently reported by different
laboratories. For postnatal exposures, behavioral effects found in more than one study at
1m g /kg-d were decreased errors on a radial arm maze in female rats and increased errors
in males dosed subcutaneously from postnatal day (PND) 1 to 4. A similar ﬁnding was seen
in rats exposed orally from PND 1 to 21 with incremental dose levels of 1, 2, and 4 mg/kg-d,
but not in rats dosed with constant dose level of 1 mg/kg-d. Neurodevelopmental behavioral,
pharmacological, and morphologic effects occurred at doses that produced signiﬁcant brain
or red blood cell acetylcholinesterase inhibition in dams or offspring.
Over the past 10 years, three cohort
studies of pregnant women and their chil-
dren were conducted investigating associa-
tions between levels of chlorpyrifos (CPF) or
metabolites in maternal urine or umbilical cord
blood and developmental neurobehavioral
outcomes (Table 1). In addition, numerous
animal studies on CPF-induced developmen-
tal neurotoxicity (DNT) effects were pub-
lished in the peer-reviewed literature (see
Tables 5–12). In view of these observations,
the objective of this review was to evaluate
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the results of the CPF-associated developmen-
tal neurobehavioral studies from epidemiologic
and in vivo animal data within a risk assessment
framework relevant to current uses of CPF in
the United States.
Approaches to evaluating epidemiologic
studies have become increasingly important to
regulatory agencies, as evidenced by the U.S.
Environmental Protection Agency (U.S. EPA)
draft proposed Framework for Incorporating
Human Epidemiologic and Incidence Data
in Health Risk Assessment (U.S. EPA 2010).
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e
n
t
t
o
t
h
e
n
e
o
n
a
t
a
l
n
u
r
s
e
r
y
,
o
r
i
n
t
h
e
m
o
t
h
e
r
’
s
p
r
i
v
a
t
e
r
o
o
m
.
T
h
e
B
N
B
A
S
w
a
s
n
o
t
a
d
m
i
n
i
s
t
e
r
e
d
i
f
t
h
e
i
n
f
a
n
t
w
a
s
a
d
m
i
t
t
e
d
t
o
t
h
e
N
e
o
n
a
t
a
l
I
n
t
e
n
s
i
v
e
C
a
r
e
U
n
i
t
(
n
=
2
1
)
;
i
f
t
h
e
i
n
f
a
n
t
w
a
s
d
e
l
i
v
e
r
e
d
a
n
d
d
i
s
c
h
a
r
g
e
d
o
v
e
r
a
w
e
e
k
e
n
d
(
n
=
4
3
)
;
i
f
t
h
e
p
a
r
e
n
t
r
e
f
u
s
e
d
(
n
=
5
)
;
i
f
t
h
e
i
n
f
a
n
t
w
a
s
n
o
t
t
e
s
t
a
b
l
e
(
n
=
2
)
;
o
r
i
f
s
t
u
d
y
p
e
r
s
o
n
n
e
l
w
e
r
e
u
n
a
v
a
i
l
a
b
l
e
(
n
=
2
2
)
.
”
E
x
p
o
s
u
r
e
m
e
a
s
u
r
e
m
e
n
t
(
C
h
e
m
i
c
a
l
/
M
e
t
a
b
o
l
i
t
e
c
&
b
i
o
l
o
g
i
c
a
l
s
p
e
c
i
m
e
n
)
C
P
F
i
n
u
m
b
i
l
i
c
a
l
c
o
r
d
b
l
o
o
d
d
T
C
P
y
i
n
m
a
t
e
r
n
a
l
u
r
i
n
e
D
E
P
s
&
D
A
P
s
i
n
m
a
t
e
r
n
a
l
a
n
d
c
h
i
l
d
u
r
i
n
e
D
E
P
s
&
D
A
P
s
i
n
m
a
t
e
r
n
a
l
u
r
i
n
e
D
E
P
s
&
D
A
P
s
i
n
m
a
t
e
r
n
a
l
u
r
i
n
e
T
i
m
i
n
g
o
f
e
x
p
o
s
u
r
e
a
s
s
e
s
s
m
e
n
t
(
a
p
p
r
o
x
.
)
A
t
d
e
l
i
v
e
r
y
D
u
r
i
n
g
p
r
e
g
n
a
n
c
y
(
m
a
t
e
r
n
a
l
p
r
e
n
a
t
a
l
)
:
1
4
a
n
d
2
6
w
e
e
k
s
g
e
s
t
a
t
i
o
n
;
a
n
a
v
e
r
a
g
e
o
f
t
h
e
s
e
t
w
o
m
e
a
s
u
r
e
s
w
a
s
c
a
l
c
u
l
a
t
e
d
D
u
r
i
n
g
p
r
e
g
n
a
n
c
y
(
m
a
t
e
r
n
a
l
p
r
e
n
a
t
a
l
)
:
1
4
a
n
d
2
6
w
e
e
k
s
g
e
s
t
a
t
i
o
n
;
a
n
a
v
e
r
a
g
e
o
f
t
h
e
s
e
t
w
o
m
e
a
s
u
r
e
s
w
a
s
c
a
l
c
u
l
a
t
e
d
D
u
r
i
n
g
p
r
e
g
n
a
n
c
y
(
m
a
t
e
r
n
a
l
p
r
e
n
a
t
a
l
)
:
3
1
w
e
e
k
s
g
e
s
t
a
t
i
o
n
P
o
s
t
n
a
t
a
l
(
c
h
i
l
d
)
:
a
g
e
6
,
1
2
,
a
n
d
2
4
m
o
n
t
h
s
P
o
s
t
-
d
e
l
i
v
e
r
y
(
m
a
t
e
r
n
a
l
)
:
7
d
a
y
s
p
o
s
t
p
a
r
t
u
m
(
C
o
n
t
i
n
u
e
d
)
111T
A
B
L
E
1
.
C
o
n
t
i
n
u
e
d
S
t
u
d
y
C
h
a
r
a
c
t
e
r
i
s
t
i
c
C
o
l
u
m
b
i
a
C
e
n
t
e
r
f
o
r
C
h
i
l
d
r
e
n
’
s
E
n
v
i
r
o
n
m
e
n
t
a
l
H
e
a
l
t
h
(
C
C
C
E
H
)
C
e
n
t
e
r
f
o
r
H
e
a
l
t
h
A
s
s
e
s
s
m
e
n
t
o
f
M
o
t
h
e
r
s
a
n
d
C
h
i
l
d
r
e
n
o
f
S
a
l
i
n
a
s
(
C
H
A
M
A
C
O
S
)
M
t
.
S
i
n
a
i
C
h
i
l
d
r
e
n
’
s
E
n
v
i
r
o
n
m
e
n
t
a
l
H
e
a
l
t
h
C
o
h
o
r
t
S
t
u
d
y
A
u
t
h
o
r
(
c
i
t
a
t
i
o
n
)
R
a
u
h
e
t
a
l
.
,
2
0
0
6
E
s
k
e
n
a
z
i
e
t
a
l
.
,
2
0
0
7
Y
o
u
n
g
e
t
a
l
.
,
2
0
0
5
E
n
g
e
l
e
t
a
l
.
,
2
0
0
7
E
x
p
o
s
u
r
e
v
a
r
i
a
b
l
e
f
o
r
m
a
t
f
o
r
a
n
a
l
y
s
i
s
C
a
t
e
g
o
r
i
c
a
l
:
>
6
.
1
7
p
g
/
g
v
s
.
≤
6
.
1
7
p
g
/
g
C
o
n
t
i
n
u
o
u
s
:
(
n
m
o
l
/
L
–
l
o
g
1
0
)
C
o
n
t
i
n
u
o
u
s
:
(
n
m
o
l
/
L
–
l
o
g
1
0
)
C
o
n
t
i
n
u
o
u
s
:
(
n
m
o
l
/
L
–
l
o
g
1
0
)
C
a
t
e
g
o
r
i
c
a
l
:
(
<
L
O
D
(
r
e
f
)
,
b
e
l
o
w
m
e
d
i
a
n
,
a
b
o
v
e
m
e
d
i
a
n
d
e
t
e
c
t
a
b
l
e
l
e
v
e
l
)
D
e
t
e
c
t
i
o
n
l
i
m
i
t
o
f
c
h
e
m
i
c
a
l
o
r
m
e
t
a
b
o
l
i
t
e
L
O
D
=
0
.
5
–
1
p
g
/
g
;
8
0
s
a
m
p
l
e
s
b
e
l
o
w
L
O
D
T
C
P
y
d
e
t
e
c
t
e
d
i
n
9
1
%
o
f
p
r
e
n
a
t
a
l
m
a
t
e
r
n
a
l
s
a
m
p
l
e
s
(
a
v
e
r
a
g
e
d
)
.
D
E
P
s
a
n
d
D
A
P
s
d
e
t
e
c
t
e
d
i
n
1
0
0
%
o
f
p
r
e
n
a
t
a
l
s
a
m
p
l
e
s
(
a
v
e
r
a
g
e
d
)
D
E
P
s
d
e
t
e
c
t
e
d
i
n
8
9
%
o
f
s
a
m
p
l
e
s
;
D
A
P
s
d
e
t
e
c
t
e
d
9
7
%
o
f
s
a
m
p
l
e
s
M
e
d
i
a
n
C
P
F
l
e
v
e
l
s
n
o
t
p
r
o
v
i
d
e
d
.
P
r
e
n
a
t
a
l
(
m
a
t
e
r
n
a
l
)
:
P
r
e
n
a
t
a
l
(
m
a
t
e
r
n
a
l
)
:
P
r
e
n
a
t
a
l
(
m
a
t
e
r
n
a
l
)
:
M
e
d
i
a
n
T
C
P
y
=
3
.
5
u
g
/
L
M
e
d
i
a
n
D
E
P
s
=
2
1
n
m
o
l
/
L
M
e
d
i
a
n
D
E
P
s
=
2
4
.
7
n
m
/
L
P
e
r
c
e
n
t
w
i
t
h
D
E
P
s
a
n
d
D
A
P
s
d
e
t
e
c
t
e
d
n
o
t
p
r
o
v
i
d
e
d
.
M
e
d
i
a
n
D
A
P
s
=
1
3
2
n
m
o
l
/
L
M
e
d
i
a
n
D
A
P
s
=
8
2
.
0
n
m
/
L
G
e
o
m
e
t
r
i
c
m
e
a
n
s
:
M
a
t
e
r
n
a
l
(
p
r
e
n
a
t
a
l
)
(
a
v
e
r
a
g
e
)
D
E
P
s
=
1
8
.
1
n
m
o
l
/
L
,
D
A
P
s
=
1
1
4
.
9
n
m
o
l
/
L
G
e
o
m
e
t
r
i
c
m
e
a
n
s
:
C
h
i
l
d
(
p
o
s
t
n
a
t
a
l
)
6
m
o
s
.
D
E
P
s
=
1
0
.
6
n
m
o
l
/
L
,
1
2
m
o
s
.
D
E
P
s
=
1
5
.
2
n
m
o
l
/
L
,
2
4
m
o
s
.
D
E
P
s
=
1
0
.
5
n
m
o
l
/
L
,
6
m
o
s
.
D
A
P
s
=
4
5
.
5
n
m
o
l
/
L
,
1
2
m
o
s
.
D
A
P
s
=
5
9
.
5
n
m
o
l
/
L
,
2
4
m
o
s
.
D
A
P
s
=
7
0
.
9
n
m
o
l
/
L
,
112S
t
u
d
y
C
h
a
r
a
c
t
e
r
i
s
t
i
c
C
o
l
u
m
b
i
a
C
e
n
t
e
r
f
o
r
C
h
i
l
d
r
e
n
’
s
E
n
v
i
r
o
n
m
e
n
t
a
l
H
e
a
l
t
h
(
C
C
C
E
H
)
C
e
n
t
e
r
f
o
r
H
e
a
l
t
h
A
s
s
e
s
s
m
e
n
t
o
f
M
o
t
h
e
r
s
a
n
d
C
h
i
l
d
r
e
n
o
f
S
a
l
i
n
a
s
(
C
H
A
M
A
C
O
S
)
M
t
.
S
i
n
a
i
C
h
i
l
d
r
e
n
’
s
E
n
v
i
r
o
n
m
e
n
t
a
l
H
e
a
l
t
h
C
o
h
o
r
t
S
t
u
d
y
A
u
t
h
o
r
(
c
i
t
a
t
i
o
n
)
R
a
u
h
e
t
a
l
.
,
2
0
0
6
E
s
k
e
n
a
z
i
e
t
a
l
.
,
2
0
0
7
Y
o
u
n
g
e
t
a
l
.
,
2
0
0
5
E
n
g
e
l
e
t
a
l
.
,
2
0
0
7
I
n
f
o
r
m
a
t
i
o
n
O
b
t
a
i
n
e
d
f
r
o
m
Q
u
e
s
t
i
o
n
n
a
i
r
e
/
I
n
t
e
r
v
i
e
w
D
e
m
o
g
r
a
p
h
i
c
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
,
h
o
m
e
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
,
l
i
f
e
t
i
m
e
r
e
s
i
d
e
n
t
i
a
l
h
i
s
t
o
r
y
,
h
i
s
t
o
r
y
o
f
a
c
t
i
v
e
/
p
a
s
s
i
v
e
s
m
o
k
i
n
g
,
o
c
c
u
p
a
t
i
o
n
a
l
h
i
s
t
o
r
y
,
m
a
t
e
r
n
a
l
e
d
u
c
a
t
i
o
n
,
i
n
c
o
m
e
l
e
v
e
l
,
a
l
c
o
h
o
l
/
d
r
u
g
u
s
e
d
u
r
i
n
g
p
r
e
g
n
a
n
c
y
,
h
i
s
t
o
r
y
o
f
r
e
s
i
d
e
n
t
i
a
l
p
e
s
t
i
c
i
d
e
u
s
e
.
T
e
s
t
o
f
N
o
n
v
e
r
b
a
l
I
n
t
e
l
l
i
g
e
n
c
e
,
H
o
m
e
O
b
s
e
r
v
a
t
i
o
n
f
o
r
M
e
a
s
u
r
e
m
e
n
t
o
f
t
h
e
E
n
v
i
r
o
n
m
e
n
t
(
H
O
M
E
)
F
a
m
i
l
y
d
e
m
o
g
r
a
p
h
i
c
s
,
w
o
r
k
h
i
s
t
o
r
i
e
s
o
f
h
o
u
s
e
h
o
l
d
m
e
m
b
e
r
s
,
m
a
t
e
r
n
a
l
b
e
h
a
v
i
o
r
s
(
s
m
o
k
i
n
g
,
a
l
c
o
h
o
l
,
d
r
u
g
u
s
e
)
,
m
a
t
e
r
n
a
l
m
e
d
i
c
a
l
h
i
s
t
o
r
y
(
p
r
e
v
i
o
u
s
p
r
e
g
n
a
n
c
i
e
s
)
P
e
a
b
o
d
y
P
i
c
t
u
r
e
V
o
c
a
b
u
l
a
r
y
T
e
s
t
(
P
P
V
T
)
,
C
e
n
t
e
r
f
o
r
E
p
i
d
e
m
i
o
l
o
g
i
c
S
t
u
d
i
e
s
D
e
p
r
e
s
s
i
o
n
S
c
a
l
e
,
H
o
m
e
O
b
s
e
r
v
a
t
i
o
n
f
o
r
M
e
a
s
u
r
e
m
e
n
t
o
f
t
h
e
E
n
v
i
r
o
n
m
e
n
t
(
H
O
M
E
)
F
a
m
i
l
y
d
e
m
o
g
r
a
p
h
i
c
s
,
w
o
r
k
h
i
s
t
o
r
i
e
s
o
f
h
o
u
s
e
h
o
l
d
m
e
m
b
e
r
s
,
m
a
t
e
r
n
a
l
b
e
h
a
v
i
o
r
s
(
s
m
o
k
i
n
g
,
a
l
c
o
h
o
l
,
d
r
u
g
u
s
e
)
,
m
a
t
e
r
n
a
l
m
e
d
i
c
a
l
h
i
s
t
o
r
y
(
p
r
e
v
i
o
u
s
p
r
e
g
n
a
n
c
i
e
s
)
E
n
v
i
r
o
n
m
e
n
t
a
l
e
x
p
o
s
u
r
e
s
,
s
o
c
i
o
d
e
m
o
g
r
a
p
h
i
c
i
n
f
o
r
m
a
t
i
o
n
,
m
e
d
i
c
a
l
h
i
s
t
o
r
y
,
l
i
f
e
s
t
y
l
e
f
a
c
t
o
r
s
.
M
e
t
h
o
d
o
f
A
s
s
e
s
s
i
n
g
C
o
n
f
o
u
n
d
i
n
g
“
C
o
v
a
r
i
a
t
e
s
w
e
r
e
i
n
c
l
u
d
e
d
i
n
m
o
d
e
l
s
a
s
p
o
s
s
i
b
l
e
c
o
n
f
o
u
n
d
e
r
s
i
f
t
h
e
y
(
1
)
h
a
d
a
s
i
g
n
i
ﬁ
c
a
n
t
a
s
s
o
c
i
a
t
i
o
n
w
i
t
h
l
e
v
e
l
o
f
p
e
s
t
i
c
i
d
e
e
x
p
o
s
u
r
e
a
n
d
a
n
y
m
e
a
s
u
r
e
o
f
d
e
v
e
l
o
p
m
e
n
t
a
l
o
u
t
c
o
m
e
s
i
n
t
h
i
s
s
a
m
p
l
e
,
(
2
)
a
l
t
e
r
e
d
t
h
e
e
s
t
i
m
a
t
e
o
f
c
h
l
o
r
p
y
r
i
f
o
s
e
f
f
e
c
t
b
y
≥
1
0
%
,
o
r
(
3
)
h
a
d
b
e
e
n
i
d
e
n
t
i
ﬁ
e
d
a
s
c
o
n
f
o
u
n
d
e
r
s
i
n
c
o
m
p
a
r
a
b
l
e
s
t
u
d
i
e
s
.
”
“
C
o
v
a
r
i
a
t
e
s
w
e
r
e
s
e
l
e
c
t
e
d
f
o
r
t
h
e
s
e
a
n
a
l
y
s
e
s
i
f
t
h
e
y
w
e
r
e
r
e
l
a
t
e
d
t
o
c
o
n
d
i
t
i
o
n
s
o
f
t
e
s
t
i
n
g
;
r
e
l
a
t
e
d
t
o
n
e
u
r
o
d
e
v
e
l
o
p
m
e
n
t
i
n
t
h
e
l
i
t
e
r
a
t
u
r
e
;
a
n
d
a
s
s
o
c
i
a
t
e
d
(
p
<
0
.
1
0
)
w
i
t
h
m
o
s
t
o
u
t
c
o
m
e
s
;
o
r
c
o
n
s
i
s
t
e
n
t
l
y
r
e
l
a
t
e
d
t
o
n
e
u
r
o
d
e
v
e
l
o
p
m
e
n
t
i
n
t
h
e
l
i
t
e
r
a
t
u
r
e
e
v
e
n
i
f
n
o
t
i
n
o
u
r
d
a
t
a
.
”
“
I
n
a
d
d
i
t
i
o
n
t
o
t
h
e
v
a
r
i
a
b
l
e
s
w
e
i
n
c
l
u
d
e
d
,
w
e
e
x
a
m
i
n
e
d
t
h
e
p
o
t
e
n
t
i
a
l
c
o
n
f
o
u
n
d
i
n
g
e
f
f
e
c
t
s
o
f
s
e
v
e
r
a
l
o
t
h
e
r
v
a
r
i
a
b
l
e
s
s
u
g
g
e
s
t
e
d
b
y
t
h
e
l
i
t
e
r
a
t
u
r
e
b
u
t
t
h
e
y
d
i
d
n
o
t
m
a
r
k
e
d
l
y
a
l
t
e
r
t
h
e
o
b
s
e
r
v
e
d
a
s
s
o
c
i
a
t
i
o
n
s
.
”
“
F
o
r
s
i
m
p
l
i
c
i
t
y
,
t
h
e
s
a
m
e
s
e
t
o
f
c
o
v
a
r
i
a
t
e
s
w
a
s
u
s
e
d
f
o
r
C
B
C
L
m
o
d
e
l
s
w
i
t
h
t
h
r
e
e
e
x
c
e
p
t
i
o
n
s
:
m
a
t
e
r
n
a
l
d
e
p
r
e
s
s
i
o
n
,
f
o
u
n
d
t
o
b
e
i
m
p
o
r
t
a
n
t
(
p
<
0
.
1
0
)
,
w
a
s
a
d
d
e
d
,
a
n
d
p
s
y
c
h
o
m
e
t
r
i
c
i
a
n
a
n
d
a
s
s
e
s
s
m
e
n
t
l
o
c
a
t
i
o
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It is also important that regulatory agencies
consider published animal studies that evalu-
ate neurodevelopmental endpoints, although
investigations may not have followed U.S.
EPA (1998a) DNT guideline requirements for
sample size (10 males and 10 females from
20 litters; 1 male or female/litter), number of
dose levels (>2), or relevant route of expo-
sure (preferably oral). Furthermore, the ani-
mal studies can contribute to understanding
the biological plausibility of outcomes that
have been associated with human exposures in
epidemiologic studies.
Previous reviews of CPF written within a
risk assessment context include two expert
panel reports by Clegg and van Gemert (1999a;
1999b), and a more recent expert panel review
(Eaton et al. 2008). Other reviews also reported
developmental outcomes associated with vari-
ous classes of pesticides (Eskenazi et al. 1999;
2008; Weselak et al. 2007), but with limited
discussion speciﬁc to potential CPF associa-
tions from epidemiologic studies. The Eaton
et al. (2008) review summarized results of
epidemiologic and toxicology studies, includ-
ing in vivo and in vitro neurodevelopmental
studies, critically evaluated human exposure
studies, and estimated dermal, oral, and inhala-
tion exposures to children and/or adults in
the general population based on currently
approved uses. A primary focus of the Eaton
et al. (2008) review was to compare dose
levels producing acetylcholinesterase activity
(AChE) inhibition with concentrations at which
in vitro or in vivo neurodevelopmental ﬁnd-
ings were reported. These levels were also
compared with exposure concentration to
which the general population may be exposed
based upon currently approved uses for CPF.
While comprehensive, the Eaton et al. (2008)
review provided narrative summaries of ﬁnd-
ings from the epidemiologic cohort studies,
rather than presenting the measures of associ-
ation and corresponding conﬁdence intervals,
thus making it difﬁcult to evaluate the pre-
cision of effect estimates and the consistency
of the direction and magnitude of associa-
tions for similar measures at similar ages across
studies.
The present review encompasses previ-
ous reviews and further contributes new anal-
yses by providing (1) in-depth analyses of
the analytical epidemiologic studies focused
on neurobehavioral outcomes in infants and
young children with comparisons of method-
ologies (including exposure measurement) and
quantitative results, consideration of the poten-
tial role of systematic error (bias), and applica-
tion of guidelines recommended by Hill (1965)
and others for evaluating causality, (2) sys-
tematic critical analyses of the in vivo devel-
opmental neurobehavioral and neuropharma-
cology studies that includes assessment of
methods and evaluation of pattern of neg-
ative and positive ﬁndings, and (3) integra-
tive evaluation of the infancy/early childhood
neurobehavioral ﬁndings with the animal data.
The studies evaluated in this review included
(1) epidemiologic studies of pregnant women
that examined associations of CPF exposure
with neurobehavioral measures in their infants
and young children published before June
2010 (Table 1) and (2) in vivo DNT animal stud-
ies with emphasis on neurobehavioral, neu-
ropharmacological and neuropathology end-
points at lower dose levels (<10 mg/kg-d) (see
Tables 5–12).
APPROACH TO EVALUATION OF CPF
STUDIES FOR HUMAN HEALTH RISK
ASSESSMENT
The following steps were undertaken in our
systematic review of published CPF animal and
epidemiologic developmental neurobehavioral
studies.
1. Identify uses and exposure patterns (includ-
ing frequency, concentration, duration, and
routes of exposure) in humans for CPF such
that relevance of animal studies can be
determined.
2. Assess evidence for possible modes of action
(MOA). In the case of CPF, risk assessments
are currently based upon an established
MOA that is acetylcholinesterase (AChE)
inhibition, and this needs to be compared
to other reported endpoints.116 A. A. LI ET AL.
3. Incorporate knowledge of the metabolism
and pharmacokinetics of CPF in the eval-
uation of exposure measures in humans
(e.g., studies evaluating outcomes associ-
ated with organophosphate [OP] metabo-
lites that include metabolites unrelated to
CPF need to be excluded or be given lower
weight in the assessment).
4. Deﬁne approach and standards for review
of human and animal studies.
a. Human: Patterns of associations within
and across different studies were eval-
uated with respect to the following
viewpoints (Hill 1964): consistency, dose
response, strength of association, and
temporality (exposure precedes out-
come). Frequency, concentration, tim-
ing (e.g., pregnancy, delivery, and early
infancy), and duration of exposure also
need to be described and compared
across studies with respect to the results.
It needs to be emphasized that lack
of association must also be considered.
For nonrandomized epidemiologic stud-
ies, consideration of sources of bias and
their potential role in inﬂuencing study
results is of critical importance.
b. Animal: The following standards were
used as guiding principles for eval-
uating the animal studies, and are
consistent with current standards for
neurodevelopmental toxicology (Adams
2010; Maurissen 2010). (1) Effects
related to litter of origin need to be
accounted for in design and statisti-
cal procedures, because maternal inﬂu-
ences during gestation and lactation
may exert signiﬁcant impact on devel-
opmental effects (DeSesso et al. 2009;
Holson and Pearce 1992; Holson et al.
2008). (2) A minimum of six animals per
treatment condition is needed to pro-
vide minimal conﬁdence in the results
(Chapin et al. 2008, 235). Ten ani-
mals per gender are required for behav-
ioral studies by U.S. EPA guidelines for
DNT testing (U.S. EPA 1998a). (3) Dose-
response evaluations need to include
more than two doses. (4) The time of
testing need to be balanced across dose
groups and other factors if data are
to be pooled in the statistical analyses
(Maurissen 2010). (5) If similar tests were
conducted at multiple ages, the statisti-
cal analyses should account for repeated
measurement, in order not to inﬂate
degrees of freedom (Holson et al. 2008;
Chapin et al. 2008, 235). (6) Compare
contemporary historical control data with
CPF generated values to assess reliability
of the methodology, variability in control
behavior, and presence of adverse effect.
This is particularly important when eval-
uating animal studies with limited dose
response data.
5. Extract and summarize all analyses con-
ducted (both signiﬁcant and non-signiﬁcant
ﬁndings), key methodological features, con-
ditions of exposure (e.g., duration, timing
and concentration), and direction and mag-
nitude of any associations in the human
and animal studies so that conclusions
about the weight of evidence will be
speciﬁc.
USES AND HUMAN EXPOSURE
Chlorpyrifos (CPF) is a widely used OP
insecticide, primarily approved for uses in agri-
cultural pest management (crop protection)
in the United States today. Most nonagri-
cultural uses such as residential control of
insect pests such as cockroaches and ter-
mites, and animal use including ﬂea and
tick control were phased out in the United
States in 2001 (U.S. EPA 2002) and in the
European Union in 2005 (Ofﬁcial Journal of
the European Union Legislation 2007). Hence,
exposures of pregnant women, infants, and
children in the general population to CPF
occur primarily through the diet and are esti-
mated to be less than 1 × 10−2 µg/kg-d in
children and 4–6 × 10−3 µg/kg-d in adults
(Eaton et al. 2008). Therefore, it is unlikely
that inhalation, dermal, or secondary oral
(nondietary) CPF exposures contribute signiﬁ-
cantly in the general population today (Eaton
et al. 2008).CHLORPYRIFOS DEVELOPMENTAL NEUROBEHAVIORAL OUTCOMES 117
Exposures to agricultural applicators includ-
ing women of childbearing age have been
estimated by the U.S. Environmental Protection
Agency (1999) to be 1.1–9.8 µg/kg-d based
on biomonitoring data for mixers, loaders, or
applicators using tractors or airplanes to apply
liquid or granular formulations. Higher daily
doses of 3–23 µg/kg-d were estimated by the
U.S. EPA for manual solo applicators using
backpack or hand wand sprayers.
Alexander et al.(2006) reported the 90th
percentile for CPF exposure from a single appli-
cation to be 7.4 µg/kg for applicators and
2.2–2.8 µg/kg for children living on the farm.
Maximal levels of CPF exposure were esti-
mated to be 16.3, 4.1, 6.3, and 2.5 µg/kg,
respectively, for applicators, spouses, children
older than 12 yr, and children younger than
12 yr. These estimates were based on levels
of 3,5,6-trichloro-2-pyridinol (TCPy), a speciﬁc
metabolite of CPF, in urine collected contin-
uously over a 4-d period immediately after
CPF was applied. Although this study estimated
exposure after only one d of application, it pro-
vides an estimate of the order of magnitude
of exposure to the farm family members who
were not applicators.
Populations living in agriculturally inten-
sive areas have potential exposures to outdoor
air concentrations ranging from 15–100 ng/m3
(Eaton et al. 2008), which results in approxi-
mate estimates of daily doses of 6 × 10−3 to
4 × 10−2 µg/kg-d assuming exposure of 4 ×
10−4 and 3 × 10−4 µg/kg-d per 1 ng/m3 for
children and adults, respectively. Using con-
servative assumptions, the absorbed dermal
exposures of 2.5 to 4 × 10−3 µg/kg-d were
estimated based on measures in homes that
recently used CPF for pest control, or in agricul-
tural homes (Eaton et al. 2008). Nondietary oral
intake rate for children are roughly estimated
to be 1.4 × 10−3 µg/kg-d in homes of farm
workers and applicators based on an assump-
tion that a 20-kg child consumes 50 mg of
dust/soil containing 700 ng CPF/g house dust
(Eaton et al. 2008).
Although most residential uses are no
longer permitted today, epidemiologic stud-
ies have been published involving previously
allowed residential exposures. Lowe et al.
(2009) estimated CPF residential exposures
to pregnant women to be 0.15 µg/kg-d
based on physiologically based pharmacoki-
netic (PBPK)/pharmacodynamic modeling and
using umbilical cord blood levels reported by
Whyatt et al. (2005) for mothers living in
New York City during a period when residen-
tial exposures to CPF were allowed. These
estimates are consistent with postapplication
residential air monitoring for CPF that indicated
levels of approximately 50–400 ng/m3 (Eaton
et al. 2008), which are approximated to result
in daily doses of 0.02–0.16 µg/kg-d for chil-
dren based on an assumption of 4 × 10−4
µg/kg-d exposure to CPF per 1 ng/m3 CPF air
concentration (Eaton et al. 2008). Exposure to
adults would be lower based on the assumption
that adults are exposed to 3 × 10−4 µg/kg-d
per 1 ng/m3 CPF (Eaton et al. 2008).
In summary, exposure to the general popu-
lation including children and women of child-
bearing age today is primarily through the
diet and in the 10−2 to 10−3 µg/kg-d dose
range. Applicators and their families may be
potentially exposed immediately after agricul-
tural application in the range of 100 and 101
µg/kg. Other estimates for exposure to women
and children living in agriculturally intensive
areas are in the 10−2 µg/kg-d dose range.
Although residential uses are no longer per-
mitted, estimates for daily exposure directly
to children and pregnant women when resi-
dential uses were allowed are in the 10−1 to
10−3 µg/kg-d dose range following dermal,
inhalation, and/or nondietary oral exposures.
Several of these estimates are based on a num-
ber of assumptions that may require further
examination. However, for the purposes of this
review, these estimates provide an initial basis
for comparison of doses used in animal stud-
ies with possible human CPF exposure levels as
recommended by Maurissen (2010).
MODE OF ACTION (MOA) AS CURRENT
BASIS FOR RISK ASSESSMENT
The best characterized MOA for acute
neurotoxic effects of CPF is inhibition of
acetylcholinesterase (AChE) activity. In order
to become an effective AChE inhibitor, CPF is118 A. A. LI ET AL.
converted to chlorpyrifos oxon (CPO) through
oxidative metabolism, which then binds to and
inhibits AChE. This binding produces inhibi-
tion of AChE leading to increased acetylcholine
(ACh) levels within synaptic clefts, hyperstimu-
lation of the cholinergic system, and adaptive
decreases in muscarinic acetylcholine receptor
(mAChR) binding (Eaton et al. 2008).
In addition to AChE inhibition in the brain,
spinal cord, and peripheral nervous system,
CPO binds to and inhibits red blood cell
(RBC) AChE, and plasma butyrylcholinesterase
(BuChE). Although the physiological role of
BuChE and RBC AChE is not clear, levels of
inhibition of the activity of these enzymes are
currently used in the U.S. as critical toxicity
endpoints for human health risk assessment,
with RBC AChE inhibition considered more
relevant than BuChE inhibition.
Age-related differences between adults and
offspring in magnitude, time of onset, and/or
recovery of brain and RBC AChE inhibition
were reported following acute dermal, oral, or
subcutaneous (sc) administration (Abu-Quare
et al. 2001; Moser et al. 1998; Moser and
Padilla 1998; Pope and Chakraborti 1992).
Although neonatal pups were more sensi-
tive than adults to higher acute CPF doses
(>10 mg/kg), there was less or absence of
differential sensitivity to CPF induced inhibi-
tion of AChE at lower (<10 mg/kg-d) repeated
exposures (Zheng et al. 2000; Liu et al.
1999). Following repeated gestational expo-
sures, maternal brain and RBC AChE inhibi-
tion was greater in dams than fetus (Mattsson
et al. 2000; Lassiter et al. 1998 1999). As dis-
cussed later in reviewing the animal literature,
cholinergic and other noncholinergic MOA
were proposed for adult and developmental
neurotoxic effects ( Aldridge et al. 2003; 2004;
Betancourt et al. 2006; 2007; Betancourt and
Carr 2004; Liu and Pope 1998; 1999; Pope
1999; Richardson and Chambers 2005; Slotkin
et al. 2006; 2007a; Zamora et al. 2008).
Although it appears that animals exposed
to CPF during gestation recover from brain
AChE inhibition more rapidly than adults due
to increased synthesis of AChE, there may
be long-lasting effects on cholinergic and
noncholinergic components (Eaton et al. 2008;
Lassiter et al. 1998; 1999; Richardson and
Chambers 2004; 2005; Slotkin et al. 2001;
2002; 2004; 2006). Therefore, this in-depth
review of the developmental neurobehavioral
animal studies compared dose levels that pro-
duced behavioral and neuropharmacological
effects in offspring, with CPF concentrations
inducing brain or AChE inhibition RBC or
plasma BuChE inhibition in offspring or dams.
In our view, from a risk assessment perspec-
tive, this dose comparison serves to determine
whether regulations based on AChE or BuChE
inhibition are protective of adverse effects that
may be due to other undeﬁned MOA.
CPF METABOLISM AND OP
BIOMARKERS OF EXPOSURE
An understanding of the relative speciﬁcity
of OP metabolites as potential biomarkers of
CPF is critical in weighing the evidence associ-
ating CPF exposure with neurobehavioral out-
comes in the human studies. The metabolism
and pharmacokinetics of CPF were described
in detail elsewhere (Eaton et al. 2008;
Timchalk et al. 2002; 2006). Brieﬂy, CPF
is metabolized to a number of metabo-
lites including chlorpyrifos-oxon (CPO), the
primary toxic active metabolite, TCPy, and
diethylphosphate (DEP) and diethylthiophos-
phate (DETP). These metabolites or their glu-
curonic or sulfate conjugates are excreted
in the urine (Barr and Angerer 2006).
Detoxiﬁcation of the oxon is brought about by
several enzymes including paraoxonases and
carboxylesterases. Paraoxonase-1 (PON1) sta-
tus based on PON1 levels or activity and
polymorphism may modulate toxicity of CPF
and CPO, but “at lower-level exposures to
CPF [<0.5 mg/kg] other esterase detoxiﬁcation
pathways would be capable of compensating
for the inter-individual differences in CPOase
activity due to PON1Q192R polymorphism”
(Cole et al. 2005).
The degree of speciﬁcity of the different
biomarkers measured in human studies to CPF
exposure is as follows (Barr and Angerer 2006;
Bravo et al. 2004):
• CPF and CPO are measured in blood and are
biomarkers of highest speciﬁcity for CPF.CHLORPYRIFOS DEVELOPMENTAL NEUROBEHAVIORAL OUTCOMES 119
• TCPy is the most common urinary biomarker
of CPF exposure, with important limitations.
For example, TCPy is also a metabolite of
CPF-methyl and triclopyr (Barr and Angerer
2006; Whyatt et al. 2009). In addition, TCPy
itself can be present in food, the environ-
ment, or homes, as a result of breakdown
products from an application of CPF or
chlorpyrifos-methyl (Barr and Angerer 2006;
Eaton et al. 2008; Whyatt et al. 2009).
Finally, signiﬁcant intraindividual variability in
repeat urine samples from the same individ-
ual was noted (Whyatt et al. 2009).
• DEPs represent a broad class of OP metabo-
lites of CPF and other OP containing
ethyl groups. DEPs include DEP , DETP , and
diethyldithiophosphate (DEDTP). Only DEP
and DETP are metabolites of CPF. As a class,
DEPs are relatively nonspeciﬁc as exposure
markers for CPF in urine because other OP
can also be degraded into DEPs.
• DMPs are a broad class of urinary
dimethylphosphate metabolites that are not
metabolites of CPF. Although DMPs are use-
ful as potential biomarkers for several methyl
OPs including malathion and CPF-methyl (a
pesticide distinct from CPF), these are not
biomarkersforCPF.Dialkylphosphates(DAPs)
are a broad class of OP urinary metabo-
lites, which include both DEPs and DMPs.
Therefore, DAPs are not speciﬁc biomarkers
forCPFbecausetheyincludemetabolitesthat
cannot be formed from CPF.
Biomarkers measured in blood provide
the highest sensitivity for measuring exposure
to the parent compound (Barr and Angerer
2006). Since this analytic method was only
recently introduced, and obtaining urine sam-
ples is more feasible and affordable, measuring
metabolite levels in urine is a common prac-
tice. Urinary metabolite levels are sensitive
to the timing of collection, which may lead
to misclassiﬁcation of exposure. For example,
Scher et al. (2007) found that results from the
ﬁrst morning void often overpredicted pesticide
concentrations based on 24-h urine samples,
which may be associated with the pharmacoki-
netics of the biomarker in the urine.
In summary, the use of urinary metabo-
lites (TCPy, DEPs, DAPs) as indicators of CPF
exposure needs to be considered with cau-
tion, because they may indicate exposure to
metabolite residues and not necessarily expo-
sure to the parent compound of concern ( Barr
and Angerer 2006; Eaton et al. 2008; Lu et al.
2005). Observed associations between levels
of nonspeciﬁc metabolites and human health
outcomes need to be interpreted cautiously
with respect to the ability to make inferences
regarding CPF speciﬁcally (Bravo et al. 2004).
ANALYSES OF NEUROBEHAVIORAL
OUTCOMES DERIVED FROM
EPIDEMIOLOGIC STUDIES
Scope of the Review and Literature
Search
Our review includes peer-reviewed
epidemiologic studies published in English
through May 31, 2010, using the follow-
ing search terms: “chlorpyrifos,” “TCPy,”
“organophosphate,” “organophosphorus,”
“neuro,” “neurotoxicity syndromes,” “neu-
rotoxic,” “neurotoxins,” “neurotoxicity,”
“neurologic,” “neurological,” “nervous sys-
tem,” “neurobehavior,” “neurobehavioral,”
“behavior,” “motor skills,” “psychomotor”
“cognitive,” “cognition,” “cognitive devel-
opment,” or “impaired cognitive function,”
“motor development,” “intelligence,” or
“autism,” “parental,” “parent,” “neonate,”
“neonatal,” “prenatal,” “pregnancy,”
“pregnant,” “fetus,” “fetal,” “maternal,”
“developmental,” “child,” “children,” “teen,”
“adolescent,” “utero.” In addition, the refer-
ence lists were cross-checked in recent reviews
on CPF to identify any relevant papers that
might have been missed by our search terms.
Studies that were included in this review
investigated potential associations between
exposure to CPF during critical periods of brain
development and neurodevelopmental out-
comes in neonates, infants, or young children.
Studies based upon self-reported exposure to
CPF, measured exposure in the home envi-
ronment (e.g., air, soil, dust), or biomarkers of
exposure were eligible, provided that exposure120 A. A. LI ET AL.
was evaluated in terms of its potential associa-
tion with a neurobehavioral measure in infants
or young children.
Population Parameters
Studies with populations potentially
exposed to CPF during critical periods of brain
development, such as in utero, infancy, and
early childhood, were included. Only studies
that were conducted on neonates, infants,
toddlers, or young children were also included.
Exposure Measurements
The CPF biomarkers reported in this review
were measured and quantiﬁed from biologi-
cal specimens obtained from women during
pregnancy or from their child after delivery.
This included measuring CPF in umbilical cord
blood, as well as measuring TCPy, DEPs, and
DAPs in maternal or child urine (Table 1).
In addition, two of the cohort studies also
reported results for DMPs (Engel et al. 2007;
Eskenazi et al. 2007; Young et al. 2005).
It is important to note that DMPs are not
biomarkers of CPF. Therefore, the results associ-
ated with DMPs are not systematically reported
and tabulated, but are discussed when relevant
to understanding results for DAPs. The use of
DAPs, which include both DEPs and DMPs,
may not be reﬂective of exposure to CPF.
The cohort studies utilized a questionnaire
to obtain demographic personal and expo-
sure information on study participants includ-
ing personal habits (i.e., smoking, alcohol con-
sumption, and drug use), maternal medical
history, and environmental exposures (includ-
ing pesticides) among the study participants
(Table 1). The extent to which information
ascertained from the questionnaires was ana-
lyzed or included (e.g., as covariates) in ﬁnal
multivariate models is summarized in Table 1.
Studies that inferred CPF exposure but did
not directly quantify CPF levels were excluded.
This included studies that evaluated CPF expo-
sure based solely on the residential location of
study participants or that estimated exposures
from ambient air on a group or community
level. Studies that reported CPF poisoning were
excluded, as were any that reported toxic
exposure levels above the approved levels
of standard use. Studies that described CPF
biomonitoring but did not report speciﬁc health
outcomes were evaluated but not included in
our ﬁnal review.
Outcome Measurements
Studies reporting neurobehavioral out-
comes including measures of psychomotor and
mental development and assessment of poten-
tial behavioral problems were evaluated. The
epidemiologic studies with respect to CPF that
assessed the neurobehavioral outcomes used
the following tools:
Bayley Scales of Infant Development II:
Mental Development Index (BSID:MDI)
The BSID:MDI assesses general cognitive
development and higher order mental process-
ing, with 178 individual items that measure
memory, habituation, generalization, classiﬁ-
cation, vocalizations, visual preference, visual
acuity skills, problem solving, early number
concepts, language, and social skills and devel-
opment (Black and Matula 2000; Sattler 2001;
Strauss et al. 2006). Standardized index scores
have a mean of 100 and a standard deviation
of 15, and range from 50 to 150 (mean
score ± 31
3 standard deviations). Infants with
standardized scores between 70 and 84 on
the BSID:MDI are classiﬁed as having “mildly
delayed performance” (Black and Matula
2000). Infants with scores <70 are classiﬁed
as having “signiﬁcantly delayed performance.”
The Mental Scale has 22 item sets, designated
by age, and each set has about 27 items (range:
20–36 items).
Bayley Scales of Infant Development II:
Psychomotor Development Index (BSID:PDI)
The BSID:PDI assesses overall motor devel-
opment and contains 111 items that mea-
sure quality of movement, sensory integra-
tion, motor planning, ﬁne and gross motor
skills (e.g., rolling, crawling, creeping, sitting,
standing, walking, running, jumping, prehen-
sion [act of holding, seizing, or grasping],
use of writing implements, imitation of hand
movements), and perceptual–motor integrationCHLORPYRIFOS DEVELOPMENTAL NEUROBEHAVIORAL OUTCOMES 121
(Black and Matula 2000; Strauss et al. 2006).
Standardized scores have a mean of 100 and
a standard deviation of 15, and range from
50 to 150 (mean score ± 31
3 standard
deviations). Classiﬁcations for “mildly delayed
performance” and “signiﬁcantly delayed per-
formance” are similar to the MDI. The
Psychomotor Scale has 22 item sets, designated
by age, and each set has about 17 items (range:
14–21 items).
Brazelton Neonatal Behavioral
Assessment Scale (BNBAS) The BNBAS
groups the measurement of behavioral abilities
and reﬂexes into the following seven domains:
habituation, orientation, motor performance,
range of state, regulation of state, autonomic
stability, number of abnormal reﬂexes, and
type of abnormal reﬂexes (Brazelton and
Nugent 1995). It has been used extensively
as a research instrument; however, it was
originally designed to be a clinical instrument,
and there are separate guidelines for research
versus clinical uses of the BNBAS. The test
is suitable for infants up to 2 mo of age and
was initially developed to help parents and
child care workers understand the language of
newborn infants, including coping capacities
and adaptive strategies. This test is also referred
to as the Neonatal Behavioral Assessment Scale
(NBAS).
Child Behavior Checklist (CBCL) The
CBCL 1.5–5 is a paper-and-pencil instrument
administered to caregivers, usually parents, of
children ages 1.5 to 5 yr of age to measure
emotional and behavioral functioning as indi-
cated by the frequency of certain behaviors
during the previous 2 mo (Achenbach and
Rescorla 2000; Rescorla 2005). CBCL items are
scored on a 3-point scale as follows: 0 = not
true, 1 = somewhat or sometimes true, and 2
= very true or often true, within the past 2 mo
(Rescorla 2005). The CBCL’s seven empirically
derived syndrome scales (emotionally reactive,
anxious/depressed, somatic complaints, with-
drawn, sleep problems, attention problems,
aggressive behavior) were developed through
factor analysis of data from the general pedi-
atric population (Rescorla 2005). In addition,
ﬁve DSM-oriented scales (affective problems,
anxiety problems, pervasive developmental
problems, attention deﬁcit/hyperactivity prob-
lems, oppositional deﬁant problems) were
developed to be relevant to the com-
monly used Diagnostic and Statistical Manual
of Mental Disorders, 4th edition (DSM-IV)
(American Psychiatric Association 2000) diag-
nostic categories, although they are not directly
equivalent to a DSM diagnosis (Rescorla 2005).
For each syndrome and DSM-oriented scale,
a child’s score is obtained by summing the
ratings for the items that compose the syn-
drome and comparing to the normative sample
as follows: <93rd percentile = normal range,
93rd to 97th percentile = borderline clinical
range, >97th percentile = clinical range. The
following three scales were evaluated by stud-
ies included in our review: Attention Problems
syndrome scale (empirically derived), the
DSM-oriented Attention-Deﬁcit/Hyperactivity
Disorder (ADHD) scale, and the DSM-
oriented Pervasive Developmental Disorder
(PDD) scale.
CHARACTERISTICS OF
EPIDEMIOLOGIC STUDIES
Four publications from three cohort studies
evaluated potential associations between CPF
exposure and neurodevelopmental outcomes
(Engel et al. 2007; Eskenazi et al. 2007; Rauh
et al. 2006; Young et al. 2005; see Table 1).
Center for Health Assessment of
Mothers and Children of Salinas
The research objective of this center
(CHAMACOS; Eskenazi et al., 2007; Young
et al. 2005) is to evaluate health effects
(e.g., growth and development) of exposure
to pesticides and other factors in the environ-
ment among pregnant women and their off-
spring who reside in Salinas Valley, California,
an agricultural community. Study partici-
pants are predominantly low-income Latina
women who enrolled in the study between
October 1999 and October 2000 during their
ﬁrst trimester of pregnancy. Approximately
531 pregnant women were followed to birth;122 A. A. LI ET AL.
however, fewer were available for analysis (i.e.,
<400), depending on the neurobehavioral out-
come, age being evaluated, and the metabolite
measurement. Information was not available in
either paper in order to calculate overall par-
ticipation rates. Urine samples were collected
from mothers twice during pregnancy and
thrice from children. Analyses relevant to our
review from this center evaluated associations
between urinary metabolites TCPy, DEPs, and
DAPs, and the BSID:MDI, BSID:PDI, CBCL,
and BNBAS. DEPs and DAPs were modeled as
continuous variables. TCPy levels were catego-
rized into three groups: less than limit of detec-
tion (<LOD), below the median detectable
level, and above the median detectable level
(Eskenazi et al. 2007).
Mount Sinai Center for Children’s
Environmental Health and Disease
Prevention Research
The enrolled cohort (Engel et al. 2007)
includes mothers recruited during pregnancy
who are multi-ethnic (about 51% Latina, 27%
black, 20% white), inner-city (New York) res-
idents, and who gave birth between May
1998 and July 2001. Maternal blood and urine
samples were collected once during the third
trimester. Engel et al. (2007) reported that 33%
of eligible women approached agreed to partic-
ipate; 404 women had available birth data and
285 of these women had usable data on DAPs
and DEPs. Engel et al. (2007) evaluated the
association between DEPs and DAPs in mater-
nal urine and the BNBAS for mother–infant
pairs. The metabolites were modeled as contin-
uous variables. Engel et al. (2007) also analyzed
the potential interaction among PON1 activ-
ity, DEPs or DAPs, and abnormal reﬂexes (one
of the seven BNBAS clusters of behaviors).
One route of inactivation of CPO is through
hydrolysis by PON1 to form TCPy.
Columbia Center for Children’s
Environmental Health Study participants
(CCCEH; Rauh et al., 2006) are nonsmoking,
inner-city (New York) mothers and their infants
born between February 1998 and May 2002,
who self-identiﬁed as black or Dominican.
Rauh et al. (2006) evaluated associations
between CPF in umbilical-cord blood and
the BSID:MDI, BSID:PDI, and CBCL in up to
254 mother–infant pairs in which the child
had reached age 36 mo (out of 536 “active
participants”). Overall participation rates could
not be calculated based on the information
provided in the paper.
Rauh et al. (2006) reported in their meth-
ods section that there was “no indication
of either a linear or nonlinear dose-response
relationship between CPF and developmental
outcomes” in preliminary analyses. The study
implemented a cutoff point of CPF exposure
at 6.17 pg/g, and CPF cord blood levels were
dichotomized above or below that value. There
were 204 participants in the <6.17 pg/ge x p o -
sure group and 50 in the >6.17 pg/g exposure
group (Table 1). The level of this threshold
was obtained by ﬁrst categorizing the CPF lev-
els as undetectable or detectable. The CPF
levels above detection were then categorized
into tertiles, and the lower bound of the high-
est tertile was 6.17 pg/g. Rauh et al. (2006)
justiﬁed the decision to implement this thresh-
old in their analysis based on three factors.
First, their previous results showed a statistically
signiﬁcant association between the highest ter-
tile of CPF exposure and birth weight (Perera
et al. 2003; Whyatt et al. 2004). Second,
preliminary analyses showed that there were
statistically signiﬁcant differences between the
PDI scores of children in the highest tertile of
CPF exposure and scores for each of the other
exposure groups. Finally, preliminary analysis
also showed statistically signiﬁcant differences
between the MDI scores of children in the high-
est tertile of CPF exposure and scores of those
in the lowest tertile, but not compared to the
undetectable group.
Cognitive and Motor Endpoints (BSID II:
MDI and PDI)
Table 2 summarizes the reported associ-
ations between CPF, TCPy, DEPs, and DAPs,
and results of the BSID:MDI and BSID:PDI for
the two studies that used this assessment tool
(Eskenazi et al. 2007; Rauh et al. 2006).T
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The CCCEH study, reported by Rauh et al.
(2006), was the only study that evaluated the
parent compound of CPF in umbilical-cord
blood, and approximately 20% of the study
population had a CPF level in the upper expo-
sure category ( >6.17 pg/g). Mean scores
(± SD) on the BSID:MDI for the total study
group were 94.0 (±9.8), 85.1 (±12.4), and
89.6 (±11.4) for ages 12, 24, and 36 mo,
respectively. Corresponding mean scores (±
SD) for the PDI by age group were 96.2
(±12.2), 97.4 (±11.5), and 100.5 (±13).
There was no statistically signiﬁcant association
between CPF exposure (>6.17 pg/gc o m p a r e d
to <6.17 pg/g) and MDI scores at 12, 24,
o r3 6m oo rP D Is c o r e sa t1 2o r2 4m oo f
age (Table 2). A statistically signiﬁcant inverse
association was observed for the PDI at 36 mo,
with children in the higher exposure cate-
gory scoring lower than children in the lower
exposure category (β =− 6.46, SE = 2.18)
(Rauh et al. 2006).
Rauh et al. (2006) also created a two-
level categorical variable to characterize perfor-
mance on the BSID. An assessment of mental
and psychomotor delay, deﬁned by the authors
as BSID scores ≤85, concluded no marked
association between CPF exposure and these
speciﬁc delays at 12 or 24 mo. However,
at 36 mo, the odds of “mental delay” and
“psychomotor delay” were statistically signiﬁ-
cantly higher among the children in the higher
exposure group (n = 50) compared to children
in the lower exposure group (n = 204), which
included the lower 2 tertiles and undetectable
groups (odds ratio [OR] = 2.37, 95% conﬁ-
dence interval [CI]: 1.08–5.19 and OR = 4.52,
95% CI: 1.61–12.7, respectively) (Rauh et al.
2006).
Rauh et al. (2006) compared the distri-
bution of CPF umbilical cord blood levels
(at birth) and 36-mo BSID scores for chil-
dren born during “preban” (before January
2000), “midban” (or “phase-out”) (January
2000 to December 2000), and “postban”
(January 2001 and later) periods. CPF levels
as mean log-transformed CPF levels at deliv-
ery were 0.92 pg/g, 0.81 pg/g, and 0.9 pg/g
for the preban, midban, and postban periods,
respectively. The corresponding mean 36-mo
BSID:MDI scores were 87.1, 91.7, and 89.5,
r e s p e c t i v e l y .T h ei n c r e a s ei nm e a nM D Is c o r e s
from preban to midban periods was statistically
signiﬁcant, whereas the subsequent decrease
was not. Comparisons of PDI scores yielded
a similar pattern (albeit statistically nonsigniﬁ-
cant), with mean scores of 97.3, 101.8, and
99.4, for preban, midban, and postban peri-
ods, respectively. These observed decreases
in cord blood and personal air sample CPF
levels coupled with increases in 36-mo MDI
and PDI scores when comparing preban with
midban time periods may suggest a crude
dose-response pattern. However, changes were
smaller and were statistically nonsigniﬁcant
when comparing preban to postban levels
(Rauh et al. 2006). This analysis was based on
different groups of participants that were tested
at different time periods and did not control
statistically for factors that may have changed
over time and may be associated with these
variables (including, but not limited to, mater-
nal IQ and HOME score). Thus, correlations of
CPF levels with changing BSID scores before
and after the ban need to be interpreted with
caution.
Eskenazi et al. (2007) also used the
BSID:MDI and BSID:PDI assessment tools
in the CHAMACOS study; however, poten-
tial exposure to CPF can only be estimated
indirectly from metabolites TCPy, DEPs, and
DAPs in maternal and child urine. In the
CHAMACOS study, there were no statisti-
cally signiﬁcant associations between TCPy and
BSID:MDI or BSID:PDI at 6, 12, or 24 mo.
The only statistically signiﬁcant ﬁnding for DEPs
indicated a positive association (“better” per-
formance) between child DEPs and the MDI
at age 12 mo (β = 1.89, 95% CI: 0.21–3.58).
There was a statistically signiﬁcant positive
association between child DAPs and BSID:MDI
at 24 mo, whereas a statistically signiﬁcant
inverse association was reported between
maternal DAPs and BSID:MDI at 24 mo (β =
−3.54, 95% CI: −6.59 to −0.49). In addition,
maternal DMPs was associated inversely (β =
−3.64, 95% CI: −6.36 −0.91) and child DMPs
was associated positively (β = 2.01, 95% CI:CHLORPYRIFOS DEVELOPMENTAL NEUROBEHAVIORAL OUTCOMES 127
0.24 - 3.78) with MDI at 24 mo. Thus, the
observed associations between DAPs and per-
formance on the BSID:MDI are not likely to be
a result primarily of exposure to CPF (Eskenazi
et al. 2007).
Both the CCCEH (cord blood CPF; Rauh
et al. 2006) and the CHAMACOS (maternal
TCPy and DEPs; Eskenazi et al. 2007) stud-
ies administered the BSID II at ages 12 and
24 mo, and showed no statistically signiﬁ-
cant associations. The CCCEH study reported
associations between CPF and indications of
poorer performance on the MDI and PDI at
age 36 mo. The inverse association between
CPF and the BSID:MDI in the CCCEH study
was statistically signiﬁcant only in the analysis
that modeled both the exposure and the out-
come as dichotomous variables (Table 2). The
CHAMACOS study did not evaluate children
at 36 mo, preventing direct comparison of
study ﬁndings. The decision to use a dichoto-
mous exposure variable in the CCCEH study
was based in part on results from previous
analyses, including analyses of CPF and birth
weight (Whyatt et al. 2004). Rauh et al. (2006)
stated, “The most highly exposed group and
the undetectable group had lower mean MDI
and PDI scores than did the middle lev-
els.” Greenland (1998) offers the following
advice regarding the categorization of expo-
sure data: “Ideal categories would be such
that any important differences in risk will exist
between them but not within them.” Thus,
it may not have been appropriate to com-
bine the “undetectable” group with the lower
two tertiles in the analyses. Furthermore, one
cannot assume a monotonic dose-response
association based on statistical evaluation of
a dichotomous variable. Therefore, the ﬁnd-
ings presented by the CCCEH study inves-
tigators do not necessarily support a dose-
response association between increasing CPF
and decreasing performance on the BSID MDI
or PDI.
The CCCEH study (Rauh et al. 2006)
was the only study that presented results for
dichotomized BSID outcomes, in addition to
using a continuous variable. The cutoff point
of 85 was based on one standard deviation
below the standardized mean score (standard-
ized mean = 100; SD = 15) (Black and
Matula 2000). In a normal distribution, one
would expect approximately 16% of scores to
be more than one standard deviation below
the mean—that is, below 85. In the CCCEH
study, 15.7, 49.3, and 32.9% had MDI scores
below 85 (“mild or signiﬁcant mental delay”)
at ages 12, 24, and 36 mo, respectively, and
14, 13.2, and 10.5% had PDI scores below
85 (“mild or signiﬁcant psychomotor delay”) at
the same ages, respectively. Thus, the distribu-
tion of PDI and MDI scores appear to differ
in this cohort. As described previously, mean
MDI scores tended to be lower than mean
PDI scores. Further evaluation of categorical
associations of CPF with BSID scores distin-
guishing “mildly delayed” from “signiﬁcantly
delayed” performance on the MDI may be
informative.
Behavioral Endpoints From the CBCL
Both the CHAMACOS and the CCCEH
cohort studies evaluated potential associations
between cord-blood CPF (Rauh et al. 2006)
or maternal and child urinary metabolites
(Eskenazi et al. 2007) with outcomes measured
by the CBCL, albeit at different ages (Table 3).
In the CCCEH cohort study, Rauh et al. (2006)
reported a statistically signiﬁcant association
among children in the higher CPF exposure
group (n = 50) compared to children in the
lower exposure group (n = 204) and results
from the CBCL assessed at age 36 mo. This
includes increased OR for attention problems
(OR = 11.26, 95% CI: 1.79–70.99), ADHD
(OR = 6.5, 95% CI: 1.09–38.69), and PDD
(OR = 5.39, 95% CI: 1.21–24.11) (Rauh et al.
2006). Although relatively high, the estimated
OR for these outcomes are imprecise, as indi-
cated by the broad 95% CI.
In the CHAMACOS study, neither mater-
nal TCPy nor maternal DEPs was statistically
signiﬁcantly associated with any of the CBCL
outcomes measured at 24 mo (Eskenazi et al.
2007). However, child metabolite levels of
DEPs and DAPs were associated with a statis-
tically signiﬁcant, approximately 70%, increaseT
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in risk of maternal-reported PDD (OR = 1.72,
95% CI: 1.12–2.64 and OR = 1.71, 95%
CI: 1.02–2.87, respectively) (Eskenazi et al.
2007). Eskenazi et al. (2007) reported posi-
tive signiﬁcant (p ≤ .05) association between
maternal levels of DAPs and PDD (OR =
2.25, 95% CI: 0.99–5.16). However, because
Eskenazi et al. (2007) noted statistically sig-
niﬁcant associations with maternal DAPs and
DMPs (OR = 2.19; 95% CI:1.05–4.58), but
not with DEPs or TCPy, evidence indicated that
exposures to pesticides other than just CPF may
be involved.
“Pervasive Developmental Disorder”
(PDD) on the CBCL includes afﬁrmative
responses to items such as “avoids eye con-
tact,” “unresponsive to affection,” and “rocks
head, body” (Eskenazi et al. 2007). PDD is one
of the “DSM-IV oriented scales” on the CBCL,
and is consistent with though not equivalent
to autism disorder and Asperger’s disorder
(Rescorla 2005; Eskenazi et al. 2007). In the
CHAMACOS study, Eskenazi et al. (2007)
combined children with scores in the clinical
range (>97th percentile) with those in the
borderline clinical range (>93rd percentile)
for the CBCL outcomes. For PDD, 29.6%
(n = 105) of the children were categorized as
being within the clinical or borderline PDD
range. Of these, 51 (14.4% overall) were in the
clinical range for PDD.
In the CCCEH study, the classiﬁcation of
PDD used by Rauh et al. (2006) appears to be
a 98th percentile cutoff point, thereby restrict-
ing their deﬁnition of PDD to “clinical” only.
Rauh et al. (2006) reported that 4.7% of the
228 children included in the CBCL analyses
were categorized as having “PDD problems.”
This corresponds to 11 children overall, with
4 children in the higher exposure group and
7 in the lower exposure group (numbers esti-
mated based on reported percentages). Despite
these relatively small numbers for analysis,
the proportion of children with maternal-
reported PDD is relatively high, particularly in
the CHAMACOS study. The extent to which
maternal-reported PDD in these studies may
correspond to a clinical diagnosis of PDD, or to
other related behavioral diagnoses, is unknown
and is an important consideration as these
cohorts continue to be followed. Preliminary
data from the CHARGE case-control study
of genetic and environmental risk factors for
autism suggest that misclassiﬁcation of PDD in
epidemiologic cohort studies is likely (Hertz-
Picciotto et al. 2006).
Interpretation of the CBCL data from
the CCCEH and CHAMACOS study should
bear in mind that assessment was con-
ducted at different ages, analyses were
based on different cutoff points for deﬁning
CBCL problems, and small numbers of out-
comes produced imprecise effect estimates.
Misclassiﬁcation of the CBCL outcomes is also
of concern.
Neonatal Behavioral Outcomes on
BNBAS
Two studies—the CHAMACOS and Mt.
Sinai study—reported associations between
maternal urinary metabolites and the BNBAS
(Table 4). The BNBAS was administered to
newborns in the CHAMACOS study within
2 mo of delivery (Young et al. 2005). The
median age at administration of the BNBAS was
3 d, with an interquartile range (IQR) between
1 and 26 d postdelivery. Young et al. (2005)
provided results for the total sample and also
stratiﬁed the infants based on the timing of their
assessment (≥ or <3 d after delivery). In the
Mount Sinai study, the BNBAS was adminis-
tered to newborns within 5 d of delivery (Engel
et al. 2007). Therefore, the data reported by
Engel et al. (2007) may be most comparable
with data <3 d after delivery reported in Young
et al. (2005).
There was no meaningful or statistical asso-
ciation between maternal DEPs and DAPs and
number of abnormal reﬂexes in analyses of
newborns tested within 3 d of birth. However,
maternal DEPs were associated inversely and
signiﬁcantly with autonomic stability among
infants tested within 3 d of birth, including
tremor, startling, and the color of the infant’s
skin (Young et al. 2005). DEPs and DAPs
were associated positively and signiﬁcantly with
number of abnormal reﬂexes in analyses ofT
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the full CHAMACOS study sample, and anal-
yses of infants evaluated 3 d or more after
birth (Table 4). Results for the remaining BNBAS
domains were variable and statistically non-
signiﬁcant, regardless of age at testing.
In the Mt. Sinai cohort study, Engel et al.
(2007) reported a statistically signiﬁcant pos-
itive association between maternal levels of
DEPs, but not DAPs, and number of abnor-
mal reﬂexes (Table 4). Results for the remaining
domains were variable and statistically non-
signiﬁcant. Engel et al. (2007) reported that the
OR for number of abnormal reﬂexes did not
increase monotonically and were not statisti-
cally signiﬁcant for the highest versus lowest
category comparisons based on analyses of
quartiles of DEPs and DAPs.
Engel et al. (2007) evaluated the inter-
action between PON1 activity and urinary
metabolites on number of abnormal reﬂexes.
The investigators considered lower tertiles of
PON1 activity to be “slower OP metaboliz-
ers.” Therefore, the implicit assumption is that
slower OP metabolizers might have higher lev-
els of CPO and other oxons. Engel et al.
(2007) noted a statistically signiﬁcant interac-
tion between levels of DAPs and PON1 activity
on the relative risk of abnormal reﬂexes. Engel
et al. (2007) reported that for DAPs and DMPs,
infants in the lowest tertile of PON1 activ-
ity displayed a signiﬁcantly increased relative
risk of abnormal reﬂexes (DAP RR = 2.38,
95% CI: 1.37–4.15; DMP RR = 1.96, 95%
CI: 1.27–3.03). A statistically signiﬁcant inter-
action was also observed between DMPs and
the middle tertile of PON1 activity. In contrast,
there was no statistically signiﬁcant interac-
tion between DEP metabolite level and PON1
activity. Therefore, the interaction between
DAPs and PON1 activity is not likely to reﬂect
consequences of CPF exposure.
The BNBAS ﬁndings that are more rele-
vant to CPF are the results from the analy-
ses of DEPs. Both studies with data reported
one or more statistically signiﬁcant associa-
tions between maternal DEPs and number of
abnormal reﬂexes. However, the implication
of these ﬁndings is not clear. Neither study
reported statistically signiﬁcant ﬁndings for any
of the other six BNBAS measures, including
motor performance. The association in the
CHAMACOS study was approximately null and
statistically nonsigniﬁcant among infants exam-
ined within 3 d of birth. Thus, results from
the two studies are not consistent when infants
of comparable ages of examination were ana-
lyzed. Testing conditions varied between the
two studies (Table 1), particularly test loca-
tion, with all infants in the Mt. Sinai study
evaluated prior to discharge, compared with
only 30% of infants in the CHAMACOS study.
Finally, both studies evaluated DEPs and DAPs,
which are not speciﬁc markers of CPF. Neither
study analyzed associations between TCPy, a
more speciﬁc urinary biomarker for CPF, and
BNBAS outcomes. In a later publication from
the CHAMACOS study, Eskenazi et al. (2007)
reported relatively low correlations between
DEPs and TCPy (r = .1 to .2).
Interpretation of Epidemiologic
Studies
Review of the three epidemiologic cohort
studies with data potentially relevant to CPF
exposure and neurobehavioral outcomes indi-
cated relatively few statistically signiﬁcant ﬁnd-
ings in the direction of adverse effects, and
no consistent patterns of adverse association
across studies. One exception may be the
positive association between DEPs and num-
ber of abnormal reﬂexes observed in both
the Mt. Sinai study (Engel et al. 2007) and
the CHAMACOS (full sample) study (Young
et al. 2005). However, the lack of associa-
tion between DEPs and number of abnormal
reﬂexes among infants evaluated within 3 d
of birth in the CHAMACOS study (beta =
0.08) is inconsistent with the statistically signif-
icant positive association reported by the Mt.
Sinai study for infants evaluated within 5 d of
delivery (RR = 1.49). Furthermore, DEPs reﬂect
exposure to several pesticides besides CPF.
Interpretation of this group of
epidemiologic studies needs to take into
consideration study similarities and differ-
ences, and strengths and limitations. ThereCHLORPYRIFOS DEVELOPMENTAL NEUROBEHAVIORAL OUTCOMES 133
are insufﬁcient data to address the spe-
ciﬁc research question regarding CPF and
neurobehavioral outcomes in infants and
young children. Isolating and quantifying
the potential effect of CPF is challenging for
several reasons. As shown in Tables 2–4, the
results were from a number of regression
models, which varied by factors including the
biomarker/metabolite measured, the age of
the infant/toddler, and the neurobehavioral
test instrument. Thus, it is also important to
consider the probability that some statistically
signiﬁcant ﬁndings may have occurred by
chance. In addition, noncausal associations
may also be produced as a result of nonran-
dom error (bias), including measurement error
and confounding.
Measurement Error All studies used
quantitative biomarkers of exposure, which is
clearly desirable because they are more objec-
tive measures compared to questionnaires.
Only one study, the CCCEH study, actually
measured the parent compound in blood.
This study was limited, however, by measur-
ing CPF at one point in time (i.e., in umbilical
cord blood at the time of delivery). The other
two cohort studies used urinary metabolites
of CPF that also reﬂect exposures to other
OP . Eskenazi et al. (2007) examined TCPy
in addition to DAPs and DEPs, but observed
no statistically signiﬁcant associations with this
metabolite. Although TCPy is more speciﬁc
than the DAPs, TCPy may reﬂect other expo-
sures (e.g., chlorpyrifos-methyl, TCPy) and may
not represent all routes of exposure equally
well (Needham 2005).
All three cohort studies relied on one or
two specimen collections and it cannot be
assumed that these data will accurately rep-
resent exposure(s) during pregnancy. Eskenazi
and colleagues (2004; 2007) reported high
within-person variability for urinary metabolites
measured at different times in both moth-
ers and their children. In addition, Eskenazi
et al. (2007) found that the proportion of
CHAMACOS study participants with biomarker
levels above the limit of detection was 71%
at the baseline pregnancy measurement and
82% at the second measurement. The average
of these two measures was reported as
91%, which ultimately becomes the reference
group for future analysis in this publication.
However, using an average limit of detec-
tion is likely to lead to misclassiﬁcation of
the exposure and also is likely to mask the
exposure level during the different times of
brain development throughout the gestational
process.
Confounding Confounding might pro-
duce spurious ﬁndings or mask “real” effects.
It is important to consider the extent to which
any factors that predict performance on the
BSID-II, or a mother’s assessment of her child
on the CBCL, or an infant’s behavior during
evaluation on the BNBAS, are related to fac-
tors associated with use of CPF or to factors that
determine the degree of exposure to CPF. Such
factors may include personal characteristics of
the mother, including her age, education level,
depressive symptoms, etc. If these factors are
not measured and controlled in the analyses,
the results may be confounded. In consider-
ing factors that are associated with levels of
CPF in umbilical cord blood, it is important
to evaluate the conditions that may be related
to the reasons for being exposed to CPF or
other OP (e.g., cockroach infestation associ-
ated with poor housing maintenance, hygiene,
and care environment; extent of participation
in agricultural work), as well as factors related
to higher versus lower exposure (e.g., following
instruction labels regarding proper use). These
factors could also be related to the learning and
developmental environment, which may affect
the test scores in the child, or may inﬂuence
the mother’s interpretation or reporting of her
child’s behavior.
It is also important to consider the con-
stellation of established predictors of perfor-
mance on the BSID, scores on the CBCL,
or scores on the BNBAS, and to evalu-
ate these as potential confounders, particu-
larly those that could conceivably be asso-
ciated with CPF levels. For example, in
their consideration of potential confounders,
Eskenazi et al. (2007) stated that selection of
covariates for the multivariate BSID-II mod-
els was based on whether the variables were134 A. A. LI ET AL.
“related to conditions of testing, related to
neurodevelopment in the literature and asso-
ciated (p < 0.1) with most outcomes ... or
consistently related to neurodevelopment in
the literature even if not in our data.” In
the CCCEH study, Rauh et al. (2006) stated
that “Covariates were included in models as
possible confounders if they (1) had a signiﬁ-
cant association with level of pesticide expo-
sure and any measure of developmental out-
comes in this sample, (2) altered the esti-
mate of CPF effect by ≥ 10%, or (3) had
been identiﬁed as confounders in comparable
studies.”
There were several differences in the fac-
tors that were adjusted for between Rauh et al.
(2006) and Eskenazi et al. (2007). For example,
Rauh et al. (2006) did not appear to mea-
sure or adjust for factors related to the BSID-II
testing environment, such as the examiner or
the exact age at examination. These factors
are known to inﬂuence test scores (Black and
Matula 2000) and were measured and adjusted
for by Eskenazi et al. (2007). As another exam-
ple, maternal depression, a signiﬁcant factor in
the Eskenazi et al. (2007) CBCL models, was
not evaluated by Rauh et al. (2006). Thus, there
are concerns about potential uncontrolled or
residual confounding.
Causal Inference Distinguishing causal
from noncausal associations in epidemiology
is challenging because of the observational
(i.e., nonrandomized) study designs and the
inevitable role of bias. Hill proposed several
viewpoints to consider when evaluating the evi-
dence from a body of epidemiologic literature,
including strength of the association, consis-
tency, dose-response, and biological plausibility
(Hill 1965). The associations (OR) between CPF
and maternal-reported CBCL outcomes were
relatively strong in the CCCEH study by Rauh
et al. (2006), but the imprecision indicated by
the accompanying CI should not be ignored.
As pointed out by Poole (2001), inference and
decision making should prefer estimates with
narrow conﬁdence intervals over small p val-
ues, “which are least vulnerable to the play
of chance. These are the results for which, by
virtue of intentional or accidental features of
our research methods, our studies provide the
most evidence.” In contrast to the results from
the CCCEH study, the association between
maternal DEPs and PDD was inverse and statis-
tically nonsigniﬁcant in the CHAMACOS study
(Eskenazi et al. 2007).
For the most part, other observed associ-
ations were not particularly strong. There was
no clear evidence for consistency, but given the
limited number of studies, different types of
exposure (home use versus agricultural), vari-
ability in exposure measure, timing of expo-
sure measure, timing of outcome measure, and
modeling of exposure and outcome for analy-
sis, only a limited degree of consistency would
be possible to establish. While there were some
statistically signiﬁcant results for analyses of
continuous exposure and outcome variables,
it was not always clearly indicated whether
the presence of nonlinear associations was also
explored. Rauh et al. (2006) and Engel et al.
(2007) did describe data that indicated that
some associations were not monotonic. Use of
dichotomous exposure variables in the CCCEH
study precluded the ability to assess exposure-
response associations in that cohort (Rauh et al.
2006). Temporality and an argument for bio-
logical plausibility were supported in the three
cohorts.
Summary
Therefore, data from these three cohorts
did not support a causal association between
CPF and adverse neurobehavioral outcomes in
infants or young children. Additional research
in this area is needed in order to assess causal-
ity with more certainty. Challenges to future
research include limited exposure among most
individuals, difﬁculties in estimating exposure
during critical periods of development, and
consistency of timing and outcomes measured
across multiple studies to allow comparisons.
Nevertheless, additional analyses from the
existing cohorts to fully examine dose response,
repeated measures of outcomes, assessment
of test–retest reliability with outcome mea-
sures, correlations among all available exposureCHLORPYRIFOS DEVELOPMENTAL NEUROBEHAVIORAL OUTCOMES 135
measures (self-report, biomarker, air monitor-
ing data), and additional follow-up time and
testing of the children will provide helpful
information.
ANALYSES OF DEVELOPMENTAL
NEUROBEHAVIORAL ANIMAL STUDIES
Scope of the Review and Literature
Search
PubMed was searched using the terms
“chlorpyrifos” and (“offspring” or “neonatal”
OR “maternal” OR “in utero” OR “develop-
ment” OR “developmental” OR “pregnancy”
OR “pregnant” OR “gestational” OR “new-
born” OR “prenatal” OR “perinatal” OR
“teratology” OR “fetus” OR “fetal” OR
“maternal” OR “age-dependent” or “age
dependent” or “age sensitivity”) AND (“brain”
OR “neuron” OR “nervous” OR “neurotoxic∗”
OR “neurolog∗” OR “neurobehavior∗”O R
“neurodevelopment” OR “developmental
neurotoxic∗” OR “motor” OR “cognition” OR
“cognitive” OR “behavior” OR “receptor” OR
“neurotransmitter” OR “cholinesterase” OR
“cerebellum” OR “hippocampus” OR “stria-
tum” OR “cortex”). In addition, the reference
list for Eaton et al. (2008) was cross-checked
for additional papers meeting our inclusion
criteria.
Our review focused on repeated-dose in
vivo DNT animal studies in which CPF alone
(i.e., not mixtures, not in sequence with other
pesticides, and not as a formulation) was
administered in a clearly deﬁned vehicle to
pregnant dams, lactating dams, and/or pups
prior to weaning. Studies using oral, inhalation,
dermal, and sc routes of exposure to CPF were
included, but not those using intravenous or
direct injections into the brain.
The primary purpose of this review
is to provide an in-depth weight-of-
evidence evaluation of the absence and
presence of effects and direction of change
reported for neurobehavioral endpoints.
Neuropharmacologic and morphologic
endpoints were evaluated for evidence of
MOA directly linking effects of these endpoints
with neurobehavioral outcomes, and relative
sensitivity compared to brain or RBC AChE
inhibition.
This review focused on evaluating effects
at lower dose levels (i.e., less than 10 mg/kg).
Studies conducted with doses near the maxi-
mum tolerated dose level, producing signiﬁcant
systemic toxicity or lethality, or designed to
compare LD50s were not included. Standard
developmental and reproduction studies were
not included unless AChE activity inhibition
or neurobehavioral, neuropharmacologic, and
neuropathologic/morphologic endpoints were
evaluated.
Sixty-one research papers measured
effects of repeated exposures of CPF during
development prior to weaning on behavioral,
neuropharmacologic (AChE inhibition, neuro-
transmitter receptor binding, neurotransmitter
levels), and/or brain pathology endpoints.
Twenty-three papers included behavioral
outcomes, 4 of which were excluded because
the test material was a CPF formulation (Muto
et al. 1992), test subjects were mutant mice
(Laviola et al. 2006), or dose levels were greater
than 10 mg/kg-d (Chanda and Pope 1996;
Chakraborti et al. 1993). Of the remaining
19 behavioral studies, there were 7 oral studies
(Braquenier et al. 2010; Carr et al. 2001;
Johnson et al. 2009; Maurissen et al. 2000;
Venerosi et al. 2006; 2009; 2010), 1 dermal
study (Abou-Donia et al. 2006), 3 sc studies
with peanut oil as vehicle (Jett et al. 2001;
Ricceri et al. 2006 [oral for gestation, sc for
postnatal]; Venerosi et al. 2008), and 8 sc stud-
ies with dimethyl sulfoxide (DMSO) as vehicle
(Aldridge et al. 2005a; Dam et al. 2000;
Billauer-Haimovitch et al. 2009; Haviland
et al. 2010; Icenogle et al. 2004; Levin et al.
2001; 2002; Ricceri et al. 2003). Seven
research papers included histopathology or
morphometry evaluations of brain areas, one
of which was excluded because CPF exposure
was 40 mg/kg-d (Amira et al. 2005). Forty-
four papers evaluated neuropharmacologic
outcomes following developmental136 A. A. LI ET AL.
exposures to repeated CPF doses less than
10 mg/kg-d.
Comparison of Experimental Design and
Statistical Analyses
Using the standards and approaches
described earlier in the section entitled
“Approach to Evaluation of CPF Studies,” the
experimental design and statistical analyses
were evaluated. Key studies representative of
groups of investigators with similar experimen-
tal design and dosing regimens are discussed
next for laboratories evaluating multiple behav-
ioral outcomes.
The oral DNT rat study by Maurissen et al.
(2000) was the most robust study in terms of
number of dose levels tested (3 dose groups
and control), number of pups (1 male or
female/litter) and litters (20 litters/dose group)
tested, and relevant route of exposure. In this
study, dams were dosed from gestational day
6 to postnatal day 11 (GD 6–PND 11). Data
for each behavioral endpoint from both sexes
were pooled into a single analysis of vari-
ance (ANOVA). This study was designed so
that the litter was the unit of analysis, the
time of testing was balanced across sex and
dose level, and experimental bias of subjective
measures was controlled (e.g., blind observa-
tions for learning and memory test). A related
study by Mattsson et al. (2000) measured AChE
or BuChE inhibition in 10 litters/dose group
(1 male or female/litter) from brain, RBC, or
plasma samples collected 2–4 h after dosing.
Three oral neurobehavioral studies dosed
mouse or rat pups directly with three CPF
dose levels or vehicle (Braquenier et al.
2010; Johnson et al. 2009; Carr et al. 2001).
Braquenier et al. (2010) tested 8–10 female
mice/dose group (1 female/litter). Of the three
behavioral tests scored by observers (locomo-
tor activity, light/dark box test, elevated plus
maze), only the elevated plus maze was scored
blind to treatment level (Braquenier et al.
2010). For the two oral rat studies, Carr et al.
(2001) and Johnson et al. (2009) dosed the
low-dose group with a constant dose level,
and exposed the mid- and high-dose groups to
incremental dose regimens. Carr et al. (2001)
dosed 2 pups/sex/litter from 5 litters/dose
group every other day, and included litter as
a factor in the statistical analysis. Observations
of the open ﬁeld activity were conducted
blind to treatment level. Johnson et al. (2009)
used a within litter design, in which all seven
exposures (corn oil vehicle, three CPF doses,
and three methylparathion doses) were repre-
sented within each litter, to the extent possible.
The potential for cross-contamination was not
addressed. The sample size for each dose group
was 9–14 rats/sex/dose level. Statistical analy-
sis included the litter as the experimental unit
of analyses, and day or week of testing was
included as a repeated-measures factor. There
was no indication of whether observers for
the radial arm maze were blind to treatment
(Johnson et al. 2009).
Oral neuropharmacologic studies by Guo-
Ross et al. (2007) and Richardson and
Chambers (2003; 2004; 2005) included two
or three dose levels other than the control,
and litter was the individual unit of analy-
sis. AChE inhibition was measured in brain
samples collected 4–6 h after dosing (Guo-
Ross et al. 2007; Richardson et al. 2005). The
selection of pups from litters and the number
of litters represented was not always clearly
indicated (Guo-Ross et al. 2007; Richardson
and Chambers 2003 2004; Tang et al. 1999).
The sample size of three to four or four to
six pups per dose group was small even for
mechanistic biochemical endpoints. However,
the use of multiple dose levels and/or times
of sacriﬁce allowed data to be evaluated
for consistency in dose-response and tem-
poral patterns. Statistical analyses for these
neuropharmacologic studies did not appear
to take into consideration repeated measures,
and a correction for multiple comparisons
was not included in the analyses. An oral
neuropharmacologic study by Eels and Brown
(2009) evaluated dopamine neurochemistry in
one oral CPF dose group receiving an incre-
mental dosing regimen (1.5 to 6 mg/kg, PND
1–21). This study was considered inadequate
because it did not report sample size for pups
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There was one dermal neurobehavioral
study that tested only one CPF exposure
level. The litter was not the experimental unit
(10 pups/sex from 5 litters; Abou-Donia et al.
2006). Observers were blind to treatment level.
Slotkin et al. (2001; 2002; 2004; 2006)
and collaborators (Aldridge et al. 2003; 2004;
2005a; 2005b; 2005c; Icenogle et al. 2004;
Levin et al. 2001; 2002; Qiao et al. 2002;
2003; 2004; Raines et al. 2001; Roy et al.
2004; 2005; Slotkin and Seidler 2005; 2007a;
2007b; Song et al. 1997) dosed rats sc with CPF
in DMSO. For 4 of the 5 neurobehavioral stud-
ies, 1 offspring/sex/dose group from 8–10 lit-
ters was tested (Aldridge et al. 2005a; Icenogle
et al. 2004; Levin et al. 2001; 2002). For
one of the neurobehavioral studies, the pup
was the individual unit of analyses with
5–7, 23–24, and 40–46 pups/sex/dose group
(2 pups/sex/litter) for locomotor skills, reﬂex
righting, and negative geotaxis, respectively
(Dam et al. 2000). The litter of origin was
confounded in studies that exposed dams dur-
ing gestation because pups were randomized
at birth to create newly constituted litters
within a treatment level. In addition, male and
female offspring from the same reconstituted
litter (1 pup/sex/litter) were pooled together
in a multivariate statistical analysis that did not
include litter as a factor. Dams were repeat-
edly rotated every few days to control for
differences in maternal care. Aldridge et al.
(2005) and Dam et al. (2000) indicated that
the observers for behavioral tests were blind to
treatment level, but Levin et al. (2001; 2002)
and Icenogle et al. (2004) did not.
The oral mouse study by Braquenier
et al. (2010) only tested female offspring, and
included 3 CPF-treated groups plus control and
8–10 pups tested per dose group. Behaviors on
the elevated plus-maze, but not the light/dark
box test, were recorded by observers blind to
treatment.
Oral and sc mouse studies conducted by
Ricceri et al. (2003; 2006) and Venerosi et al.
(2006; 2008; 2009; 2010) dosed approxi-
mately 10 pups/dose level. With the exception
of Ricceri et al. (2006), these studies indicated
that observers were blind to treatment level for
at least one of the behavioral measures. Mice
were exposed to only one CPF dose level in
2 oral studies (6 mg/kg-d; Venerosi et al. 2009;
2010) and 1 sc study (3 mg/kg-d in peanut
oil; Venerosi et al. 2008). Ricceri et al. (2003)
dosed mice postnatally with two CPF dose lev-
els sc in DMSO. For each oral group of dams
dosed during pregnancy (vehicle, 3 mg/kg-
d, or 6 mg/kg-d), Ricceri et al. (2006) and
Venerosi et al. (2006) dosed the pups (vehi-
cle, 1 mg/kg-d, or 3 mg/kg-d) sc and orally,
respectively, using a within-litter design such
that in total nine different treatment groups
were established. The litter was the experimen-
tal unit of analyses for most studies, although
not always for behavioral endpoints examined
after weaning (Ricceri et al. 2003). The deci-
sion tree for the statistical analyses was unclear
because results of post hoc tests were reported
even though main effects were not signiﬁcant
(Ricceri et al. 2003; 2006; Venerosi et al.
2009). Frequency, duration, and latency for
many behavioral parameters were analyzed.
Corrections for the multiple comparisons were
reported in two papers (Ricceri et al. 2003;
2006).
Relevance of Route, Vehicle, and Age of
Exposure to Risk Assessment
The route and age of exposure, as well
as the vehicle used, need to be taken into
account in the interpretation and application
of the results in animals for human health risk
assessment. The relevance of different routes of
exposure depends on the speciﬁc population of
concern and uses of CPF. In the United States
today, the primary route of exposure for the
general population is dietary. The majority of
the animal studies on CPF can be divided into
the following periods of exposure: (1) gesta-
tional exposures to the dam, (2) gestational and
postnatal exposure to the dam, so that pups
are potentially exposed via lactation, (3) ges-
tational exposures followed by direct expo-
sures to the pups, or (4) postnatal exposures
directly to the pup without any maternal expo-
sures. Our review evaluates outcomes follow-
ing gestational exposures separately from those138 A. A. LI ET AL.
following direct exposure to pups for each out-
come because the developmental period of
exposure is an important consideration when
evaluating the results.
Although different routes of exposure or
vehicles may be used in mechanistic studies,
the relevance of the methods must be evalu-
ated when these data are considered for set-
ting acceptable exposure levels for human risk
assessment. Oral administration of test material
is relevant to dietary exposures, which is the
primary route of exposure for CPF to the gen-
eral population. However, bolus gavage dose
of CPF in corn oil may result in peak blood
and brain levels that may not be similar to
those measured following dietary exposures,
the primary route of exposure to children in
the United States where residential uses are
not allowed. The sc route of exposure is not
a human route of exposure. One rationale for
using the sc route of exposure in animal stud-
ies is that it “avoids the potential confounds
of differential rates of gastrointestinal absorp-
tion between compounds or ages and ﬁrst-pass
effects on bioavailability” (Slotkin et al. 2006).
However, when evaluating data for purposes of
human health risk assessment, ﬁrst-pass effects
on bioavailability are important considerations.
Carr and Nail (2008) studied the effects
of route, vehicle, and volume of exposure on
brain AChE inhibition 4 h after CPF oral and
sc exposure to 5 mg/kg to pups from PND
10 to 16. Overall, sc DMSO injections of CPF
increased regional brain AChE inhibition by
16–29% compared to levels in pups dosed
orally. Carr and Nail (2008) reported statistically
signiﬁcant decreases in body weight after d 4 of
sc injections but not after gavage dosing. Thus,
sc DMSO injections of CPF increased toxicity
compared to corn oil gavage doses as measured
by AChE inhibition and body weight decreases.
Carr et al. (2001) also pointed out that sc injec-
tion could mimic dermal exposure, but “it does
not appropriately consider the disposition and
metabolism . . . when penetration through the
skin is a determining factor.”
Marty et al. (2007) measured the blood
PK for CPF and its major metabolite TCPy fol-
lowing gavage and sc dosing to pups on PND
5. Signiﬁcant (56 ± 36%) radiolabeled CPF
remained at the site of sc injection at the
time to maximum concentration (Tmax = 2 h).
Smith et al. (2009) compared CPF PK using oral
and sc exposures and different vehicles in adult
male rats. Orally administered CPF underwent
much more extensive metabolism than CPF
administered sc, consistent with hypothesis that
oral CPF is rapidly absorbed and extensively
metabolized in the gut and liver, resulting in
greater ﬁrst-pass metabolism. In addition, PBPK
model simulation in adults show that sc admin-
istration in corn oil and DMSO is predicted to
have “greatly prolonged inhibition of ChE activ-
ity in the brain relative to oral exposure,” due
to “slow release of CPF from the injection site
depot and localized brain CPF metabolism to
CPF-oxon” (Smith et al. 2009).
DMSO, by itself, perturbs behavior, neu-
ropathology, or neuropharmacology at volumes
administered as a vehicle. Speciﬁcally 20-µl
injections of DMSO in PND 4 rats produced
endocrine and neurochemical changes simi-
lar to or additive with chlordecone (Rosecrans
et al. 1984; Uphouse et al. 1982). DMSO exac-
erbated the neuropathological effects of soman
in adult rats at 1-ml/kg doses (Ballough et al.
2008), which is the equivalent volume used
in CPF sc rat studies (Aldridge et al. 2003;
Levin et al. 2002). These studies indicated
that use of DMSO as a vehicle is a potential
confounder for determination of cellular and
pharmacologic effects produced by chemicals.
In summary, the relevance of sc injec-
tions of CPF in DMSO to dietary exposures
for risk assessment is called into question
due to (1) differences in PK resulting from
a depot of test material at the site of the
local sc injection including bypassing ﬁrst pass
metabolism, (2) the possible impact of DMSO
itself on neurotoxicity, and (3) resultant effects
on toxicology endpoints that may not be repre-
sentative of human dietary exposures to CPF.
Neurobehavioral Domains
This section evaluates consistency of
effects across different laboratories for similar
behavioral domains. Tables 5–10 summarizeCHLORPYRIFOS DEVELOPMENTAL NEUROBEHAVIORAL OUTCOMES 139
neurobehavioral effects of CPF exposures on
selected behaviors for which there were data
from different laboratories. An exception was
made for spontaneous alternation, measured
only by one laboratory (Table 8), because this
behavior was considered to be related to other
measures associated with learning and mem-
ory and/or activity in a novel environment.
The major methodological issues of concern
were discussed in the previous section and
were taken into consideration in the overall
assessment.
Developmental Landmarks, Neuro-
developmental Reﬂex, and Ultrasonic
Vocalizations Prior to Weaning Overall,
CPF exposures did not produce a consistent
pattern of adverse effects on developmental
landmarks, neurodevelopmental reﬂex and
ultrasonic vocalization (USV) measured prior to
weaning at doses below 5 mg/kg-d (Table 5).
Gestational exposures Maurissen et al.
(2000) reported effects on developmental land-
marks in rats only at the highest dose level of
5m g /kg, which was maternally toxic and pro-
duced 25% pup mortality and decreased pup
body weight before culling on PND 4. Billauer-
Haimovitch et al. (2009) noted no marked
effects in mice at doses from 1 to 10 mg/kg-d
following gestational sc exposures. The sample
size for the latter study was not reported and
half the pups were cross-fostered.
In mice, 6-mg/kg CPF exposure from GD
14 to 17 exerted little impact on pup growth
and sensorimotor development (Table 5B;
Venerosi et al., 2009). There was a numeri-
cal trend toward delayed appearance of hind-
limb grasping and decreased total daily quali-
tative score (comprising all seven reﬂex mea-
sures including hind limb grasping) (Venerosi
et al. 2009). Venerosi et al. (2009) concluded
that “a deﬁnitive conclusion about a retard-
ing CPF effect cannot be drawn” based on
this data. There were statistically signiﬁcant
decreases in pivoting frequency and duration
and increases in duration of “immobility” at
PND 12, but no signiﬁcant effect on frequency
or duration of crossing, head moving and wall
climbing (Table 5B). The signiﬁcance of the
decreases in pivoting to overall motor abilities is
uncertain given the low control values (approx-
imately 3–4 frequency and 2–3 s). Thus far, the
evidence for adverse effects on sensorimotor
development is not compelling.
Exposures to 6 mg/kg from GD 14 to
17 decreased USV and higher peak frequency
of calls at PND 10 but not PND 4 and 7 in
male mouse pups isolated from the dam for
4 min (Table 5C; Venerosi et al., 2009). The
CPF-treated mice had 80 and 15 USV calls/min
on PND 7 and 10, respectively. The controls
had 70 and 40 USV calls/min, respectively. It is
premature to conclude that the fall in USV at
6m g /kg-d (the only dose level tested) following
gestational exposures is an adverse effect based
on a study testing only one dose level. In addi-
tion, the overall pattern of rapid decrease in
USV in mice at 6 mg/kg Venerosi et al. (2009) is
consistent with the ontogenic proﬁle for control
mice in two other studies from this labora-
tory. Speciﬁcally, Ricceri et al. (2003) observed
a rapid decline in USV calls in control pups
(approximately 125, 80, and 20 USV calls/min
on PND 5, 8, 11, respectively). Calamandrei
et al. (1999) reported USV decreasing from
approximately 70 to 20 USV/min on PND
7 and PND 11, respectively.
Postnatal exposures Johnson et al. (2009)
noted no signiﬁcant effects of oral low
(1 mg/kg-d), mid (incremental 1, 2, and
4m g /kg-d) and high (incremental 1.5, 3, and
6m g /kg-d) doses of CPF from PND 1 to
21 on 5 physical development parameters
(pinna detachment, downy fur development,
hair growth, incisor eruption and eye opening)
and 5 neurodevelopmental reﬂex parameters
(surface righting, negative geotaxis, cliff avoid-
ance, free fall righting, and acoustic startle)
(Table 5A). This was a robust study measuring
effects of direct dosing to pups on physical and
reﬂex development at three dose levels that
produced statistically signiﬁcant hippocampal
AChE inhibition (14–53%) on PND 20.
Ricceri et al. (2003) reported no signiﬁcant
effects of 1 and 3 mg/kg-d CPF (sc DMSO)
from PND 1 to 4 on USV or homing behavior
in mice (Table 5C). Dam et al. (2000) showed
that 1 mg/kg-d CPF (sc DMSO) injected in rats
from PND 1 to 4 increased surface rightingT
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reﬂex time and decreased the number of ani-
mals meeting the criterion for negative geotaxis
(180◦ turn on an inclined surface) in female
mice but not male mice (Table 5A). Brain AChE
inhibition was 75% at 2 h after dosing on PND
1 (Dam et al. 2000). The study by Dam et al.
(2000) was limited because only one CPF dose
level in DMSO was tested, and the litter was
not the experimental unit for data analysis.
Motor Activity There were mixed results
(increases, decreases, and no effect) on motor
activity (Table 6), as measured in the open ﬁeld
or automated devices. Some studies reported
a tendency for increased activity as measured
by increased total session activity, decreased
intersession habituation, and/or reduced lin-
ear trend (slope) of the habituation curve.
However, as discussed next, the weight of evi-
dence does not support a consistent effect at
lower exposure levels (i.e., <5m g /kg) follow-
ing gestational, lactational, or direct postnatal
exposures to the pup.
Gestational exposures with or without
postnatal exposures Maurissen et al. (2000)
reported a decrease in automated motor activ-
ity at PND 13 and increases at PND 17, 21,
and 60 in rats following gestational and lac-
tational exposures to 5 mg/kg, but not at
1o r0 . 3m g /kg (Table 6A). None of these
effects at 5 mg/kg were statistically signiﬁcant.
The lack of effect at lower doses is consis-
tent with two oral mouse studies, in which
no marked effects on observer-measured open-
ﬁeld activity (number of line crossing) were
demonstrated following in utero exposure to
0.2–6 mg/kg (Braquenier et al. 2010; Venerosi
et al. 2009) (Table 6C).
In contrast, Ricceri et al. (2006) found
increases in frequency of crossing in an open
ﬁeld at PND 70 in offspring of dams dosed
orally with CPF during gestation. In this study,
mice were dosed with nine possible combina-
tions of gestational gavage exposures to dams
( 0 ,3 ,o r6m g /kg-d) and postnatal sc (peanut
oil) injection to pups (0, 1, or 3 mg/kg-d)
were tested (Table 6C). Speciﬁcally, prenatal
exposure to 3 mg/kg-d in combination with
postnatal sc exposure to 3 mg/kg, but not
1m g /kg or saline, produced an elevation in
activity during the ﬁrst 5 min of the 20-min ses-
sion (Table 6C: 3/3 dose group). In addition,
elevations in activity were observed in mice
exposed in utero to 6 mg/kg-d and postnatally
to vehicle or 1 mg/kg-d (Table 6C: 6/0a n d
6/1 dose group), but not in mice exposed in
u t e r ot o6m g /kg-d and postnatally to 3 mg/kg-
d( T a b l e6 C :6 /3 dose group). Ricceri et al.
(2006) postulated that the higher postnatal
d o s eo f6m g /kg-d offset the effects of prenatal
doses.
Icenogle et al. (2004) and Levin et al.
(2002) dosed rat dams with 1 or 5 mg/kg CPF
sc in DMSO during early (GD 9–12) or later
(GD 17–20) gestation, and reported effects in
opposite directions (Table 6B). Icenogle et al.
(2004) noted greater habituation at 5 but not
at 1 mg/kg-d, and signiﬁcant decrease in activ-
ity in 2 of 12 time blocks toward the end of the
session. This resulted in a higher linear trend
(faster rate of decrease) in males and females
at 5 mg/kg-d. In contrast, Levin et al. (2002)
showed less habituation at 1 and 5 mg/kg, as
measured by a lower linear trend (slower rate
of decrease) in females only.
Caution is needed in evaluating data con-
verted into linear trend values, which is deﬁned
in the ﬁgure legends as the “slope of decrease
in activity over consecutive 5-min blocks”
(Icenogle et al. 2004; Levin et al. 2002). The
linear trend analysis is based on ﬁtting lin-
ear functions to nonlinear habituation curves
with insufﬁcient information provided on good-
ness of ﬁt to indicate how well they represent
the actual data. Based on evaluation of the
actual habituation data, there were no marked
effects on habituation at 1 mg/kg-d follow-
ing GD 9–12 exposures (Icenogle et al. 2004,
Figure 2), nor at 1 or 5 mg/kg-d following GD
17–20 exposures (Levin et al. 2002, Figure 2).
The linear trend values for the CPF groups were
approximately 1.2 (GD 17–20, 1 and 5 mg/kg)
and 1.6 (GD 9–12, 5 mg/kg). These values
are within control linear trend values ranging
from 1.2 to 1.6 for three studies published by
the same laboratory (Levin et al. 2001 2002;
Icenogle et al. 2004).
One dermal study conducted by the Abou-
Donia et al. (2006) measured effects of CPFT
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m
e
C
a
g
e
A
c
t
i
v
i
t
y
(
1
h
o
u
r
)
A
u
t
o
m
a
t
e
d
T
i
m
e
o
f
t
e
s
t
i
n
g
b
a
l
a
n
c
e
d
a
c
r
o
s
s
d
o
s
e
l
e
v
e
l
a
n
d
s
e
x
G
D
6
-
P
N
D
1
0
O
r
a
l
c
o
r
n
o
i
l
P
N
D
1
3
N
=
2
0
l
i
t
t
e
r
s
;
1
p
u
p
/
s
e
x
/
l
i
t
t
e
r
Y
e
s
,
l
i
t
t
e
r
i
s
u
n
i
t
,
L
i
t
t
e
r
w
a
s
a
f
a
c
t
o
r
i
n
t
h
e
s
t
a
t
i
s
t
i
c
a
l
a
n
a
l
y
s
i
s
T
o
t
a
l
A
c
t
i
v
i
t
y
0
b
0
(
↓
)
c
P
N
D
1
7
H
a
b
i
t
u
a
t
i
o
n
0
0
0
T
o
t
a
l
A
c
t
i
v
i
t
y
0
0
(
↑
)
H
a
b
i
t
u
a
t
i
o
n
0
0
0
T
o
t
a
l
A
c
t
i
v
i
t
y
0
0
(
↑
)
P
N
D
2
1
H
a
b
i
t
u
a
t
i
o
n
0
0
0
T
o
t
a
l
A
c
t
i
v
i
t
y
0
0
(
↑
)
P
N
D
6
0
H
a
b
i
t
u
a
t
i
o
n
0
0
0
C
a
r
r
e
t
a
l
.
,
2
0
0
1
O
p
e
n
F
i
e
l
d
(
3
m
i
n
f
o
r
P
N
D
1
0
,
1
2
;
6
m
i
n
f
o
r
P
N
D
1
4
–
2
0
)
V
i
d
e
o
c
a
m
e
r
a
,
m
e
a
s
u
r
e
s
f
r
o
m
2
t
e
c
h
n
i
c
i
a
n
s
a
v
e
r
a
g
e
d
f
o
r
e
a
c
h
r
a
t
;
b
l
i
n
d
a
n
d
s
e
m
i
-
b
a
l
a
n
c
e
d
P
N
D
1
–
2
1
(
p
u
p
s
d
o
s
e
d
e
v
e
r
y
o
t
h
e
r
d
a
y
)
O
r
a
l
c
o
r
n
o
i
l
P
N
D
1
0
,
1
2
,
1
4
,
1
6
,
1
8
,
2
0
2
m
a
l
e
s
a
n
d
2
f
e
m
a
l
e
s
p
e
r
l
i
t
t
e
r
f
r
o
m
5
l
i
t
t
e
r
s
Y
e
s
,
l
i
t
t
e
r
i
s
u
n
i
t
,
L
i
t
t
e
r
w
a
s
a
f
a
c
t
o
r
i
n
t
h
e
s
t
a
t
i
s
t
i
c
a
l
a
n
a
l
y
s
i
s
L
i
n
e
c
r
o
s
s
e
s
(
f
r
o
n
t
2
p
a
w
s
)
M
0
F
0
f
o
r
e
a
c
h
o
f
6
a
g
e
s
M
0
F
0
f
o
r
e
a
c
h
o
f
6
a
g
e
s
M
0
F
0
f
o
r
e
a
c
h
o
f
6
a
g
e
s
P
N
D
2
5
M
0
F
0
M
↓
F
↓
M
↓
F
↓
P
N
D
3
0
M
0
F
0
M
↓
F
↓
M
↓
F
↓
a
C
a
r
r
2
0
0
1
d
o
s
e
d
a
n
i
m
a
l
s
w
i
t
h
i
n
c
r
e
m
e
n
t
a
l
l
y
h
i
g
h
e
r
d
o
s
e
s
a
s
a
n
i
m
a
l
s
g
o
t
o
l
d
e
r
b
A
l
l
e
n
t
r
i
e
s
w
i
t
h
o
u
t
“
M
”
a
n
d
/
o
r
“
F
”
i
n
d
i
c
a
t
e
s
a
n
a
l
y
s
e
s
i
s
b
a
s
e
d
o
n
m
a
l
e
s
a
n
d
f
e
m
a
l
e
s
c
o
m
b
i
n
e
d
.
c
(
)
i
n
d
i
c
a
t
e
s
c
h
a
n
g
e
s
r
e
p
o
r
t
e
d
b
y
t
h
e
a
u
t
h
o
r
s
w
e
r
e
n
o
t
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
ﬁ
c
a
n
t
∗
I
f
s
t
a
t
i
s
t
i
c
a
l
a
n
a
l
y
s
e
s
o
r
m
e
a
s
u
r
e
s
w
e
r
e
d
e
s
c
r
i
b
e
d
i
n
m
e
t
h
o
d
s
,
t
h
e
n
i
t
w
a
s
i
n
c
l
u
d
e
d
a
n
d
l
i
s
t
e
d
a
s
“
0
”
i
f
n
o
t
r
e
p
o
r
t
e
d
t
o
b
e
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
ﬁ
c
a
n
t
144T
A
B
L
E
6
B
.
M
o
t
o
r
a
c
t
i
v
i
t
y
i
n
t
h
e
R
A
T
(
s
c
D
M
S
O
)
M
a
g
n
i
t
u
d
e
o
f
D
o
s
e
T
e
s
t
e
d
,
m
g
/
k
g
-
d
a
y
A
u
t
h
o
r
T
e
s
t
A
g
e
a
n
d
r
o
u
t
e
o
f
E
x
p
o
s
u
r
e
A
g
e
T
e
s
t
i
n
g
S
a
m
p
l
e
S
i
z
e
p
e
r
D
o
s
e
L
e
v
e
l
(
Y
e
s
/
N
o
L
i
t
t
e
r
i
s
U
n
i
t
)
M
e
a
s
u
r
e
∗
1
5
I
c
e
n
o
g
l
e
e
t
a
l
.
,
2
0
0
4
F
i
g
u
r
e
-
8
m
a
z
e
(
1
h
o
u
r
w
i
t
h
1
2
5
-
m
i
n
b
l
o
c
k
s
)
G
D
9
–
1
2
s
c
D
M
S
O
W
k
4
–
8
1
0
M
+
1
0
F
;
1
0
l
i
t
t
e
r
s
(
1
r
a
t
/
s
e
x
/
r
e
c
o
n
s
t
i
t
u
t
e
d
l
i
t
t
e
r
)
L
i
t
t
e
r
o
f
o
r
i
g
i
n
i
s
n
o
t
u
n
i
t
d
u
e
t
o
r
a
n
d
o
m
i
z
a
t
i
o
n
o
f
p
u
p
s
t
o
d
a
m
s
a
t
b
i
r
t
h
.
H
a
b
i
t
u
a
t
i
o
n
a
(
C
P
F
x
B
l
o
c
k
)
0
↑
(
↓
a
c
t
i
v
i
t
y
t
i
m
e
b
l
o
c
k
9
,
1
1
o
f
1
2
)
A
u
t
o
m
a
t
e
d
L
i
n
e
a
r
t
r
e
n
d
o
f
h
a
b
i
t
u
a
t
i
o
n
b
,
0
↑
s
l
o
p
e
Q
u
a
d
r
a
t
i
c
t
r
e
n
d
o
f
h
a
b
i
t
u
a
t
i
o
n
∗
0
0
L
e
v
i
n
e
t
a
l
.
,
2
0
0
2
F
i
g
u
r
e
-
8
m
a
z
e
(
1
h
o
u
r
w
i
t
h
1
2
5
-
m
i
n
b
l
o
c
k
s
)
A
u
t
o
m
a
t
e
d
G
D
1
7
–
2
0
s
c
D
M
S
O
W
k
4
–
6
1
0
M
+
1
0
F
;
1
0
l
i
t
t
e
r
s
(
1
r
a
t
/
s
e
x
/
r
e
c
o
n
s
t
i
t
u
t
e
d
l
i
t
t
e
r
)
L
i
t
t
e
r
o
f
o
r
i
g
i
n
i
s
n
o
t
u
n
i
t
d
u
e
t
o
r
a
n
d
o
m
i
z
a
t
i
o
n
o
f
p
u
p
s
t
o
d
a
m
s
a
t
b
i
r
t
h
.
M
e
a
n
a
c
t
i
v
i
t
y
0
0
H
a
b
i
t
u
a
t
i
o
n
(
C
P
F
x
B
l
o
c
k
)
M
0
F
(

)
d
M
0
F
(

)
d
L
i
n
e
a
r
t
r
e
n
d
o
f
h
a
b
i
t
u
a
t
i
o
n
M
0
F
↓
s
l
o
p
e
M
0
F
↓
s
l
o
p
e
Q
u
a
d
r
a
t
i
c
t
r
e
n
d
o
f
h
a
b
i
t
u
a
t
i
o
n
∗
0
0
L
e
v
i
n
e
t
a
l
.
,
2
0
0
1
F
i
g
u
r
e
-
8
m
a
z
e
(
1
h
o
u
r
w
i
t
h
1
2
5
-
m
i
n
b
l
o
c
k
s
)
A
u
t
o
m
a
t
e
d
P
N
D
1
–
4
(
i
n
i
t
i
a
l
p
o
o
l
e
d
a
n
a
l
y
s
i
s
w
i
t
h
P
N
D
1
1
–
1
4
,
s
e
e
b
e
l
o
w
)
s
c
D
M
S
O
W
k
4
–
6
1
0
M
+
1
0
F
;
o
n
a
v
e
r
a
g
e
t
h
e
r
e
w
a
s
1
r
a
t
/
s
e
x
/
l
i
t
t
e
r
L
i
t
t
e
r
i
s
n
o
t
u
n
i
t
f
o
r
i
n
i
t
i
a
l
p
o
o
l
e
d
a
n
a
l
y
s
i
s
c
o
m
b
i
n
i
n
g
M
&
F
M
e
a
n
a
c
t
i
v
i
t
y
0
H
a
b
i
t
u
a
t
i
o
n
(
C
P
F
x
B
l
o
c
k
)
0
L
e
v
i
n
e
t
a
l
.
,
2
0
0
1
F
i
g
u
r
e
-
8
m
a
z
e
(
1
h
o
u
r
w
i
t
h
1
2
5
-
m
i
n
b
l
o
c
k
s
)
A
u
t
o
m
a
t
e
d
P
N
D
1
1
–
1
4
(
i
n
i
t
i
a
l
p
o
o
l
e
d
a
n
a
l
y
s
i
s
w
i
t
h
P
N
D
1
–
4
;
s
e
e
a
b
o
v
e
)
s
c
D
M
S
O
W
k
4
–
6
1
0
M
+
1
0
F
;
o
n
a
v
e
r
a
g
e
t
h
e
r
e
w
a
s
1
r
a
t
/
s
e
x
/
l
i
t
t
e
r
L
i
t
t
e
r
i
s
n
o
t
u
n
i
t
f
o
r
i
n
i
t
i
a
l
p
o
o
l
e
d
a
n
a
l
y
s
i
s
c
o
m
b
i
n
i
n
g
M
&
F
M
e
a
n
a
c
t
i
v
i
t
y
0
H
a
b
i
t
u
a
t
i
o
n
(
C
P
F
x
B
l
o
c
k
)
I
n
t
e
r
a
c
t
i
o
n
n
o
t
r
e
p
o
r
t
e
d
L
i
n
e
a
r
t
r
e
n
d
o
f
h
a
b
i
t
u
a
t
i
o
n
↓
s
l
o
p
e
(
C
o
n
t
i
n
u
e
d
)
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C
o
n
t
i
n
u
e
d
M
a
g
n
i
t
u
d
e
o
f
D
o
s
e
T
e
s
t
e
d
,
m
g
/
k
g
-
d
a
y
A
u
t
h
o
r
T
e
s
t
A
g
e
a
n
d
r
o
u
t
e
o
f
E
x
p
o
s
u
r
e
A
g
e
T
e
s
t
i
n
g
S
a
m
p
l
e
S
i
z
e
p
e
r
D
o
s
e
L
e
v
e
l
(
Y
e
s
/
N
o
L
i
t
t
e
r
i
s
U
n
i
t
)
M
e
a
s
u
r
e
∗
1
5
D
a
m
e
t
a
l
.
,
2
0
0
0
O
p
e
n
ﬁ
e
l
d
(
5
-
m
i
n
u
t
e
)
V
i
d
e
o
t
a
p
e
d
a
n
d
b
l
i
n
d
t
o
t
r
e
a
t
m
e
n
t
P
N
D
1
–
4
s
c
D
M
S
O
P
N
D
2
1
5
–
7
p
u
p
s
/
s
e
x
f
r
o
m
u
n
s
t
a
t
e
d
n
u
m
b
e
r
o
f
l
i
t
t
e
r
s
(
M
e
t
h
o
d
s
s
t
a
t
e
2
p
u
p
s
/
s
e
x
/
l
i
t
t
e
r
)
L
i
t
t
e
r
i
s
n
o
t
u
n
i
t
N
u
m
b
e
r
o
f
s
q
u
a
r
e
s
c
r
o
s
s
e
d
M
↓
F
0
R
e
a
r
i
n
g
M
↓
F
0
S
e
l
f
-
g
r
o
o
m
i
n
g
M
0
F
0
P
N
D
3
0
S
a
m
e
a
s
f
o
r
P
N
D
2
1
N
u
m
b
e
r
o
f
s
q
u
a
r
e
s
c
r
o
s
s
e
d
M
↓
F
0
R
e
a
r
i
n
g
M
↓
F
0
S
e
l
f
-
g
r
o
o
m
i
n
g
M
0
F
0
D
a
m
e
t
a
l
.
,
2
0
0
0
O
p
e
n
ﬁ
e
l
d
(
5
-
m
i
n
u
t
e
)
V
i
d
e
o
t
a
p
e
d
a
n
d
B
l
i
n
d
t
o
t
r
e
a
t
m
e
n
t
P
N
D
1
1
–
1
4
s
c
D
M
S
O
P
N
D
2
1
5
–
7
p
u
p
s
/
s
e
x
f
r
o
m
u
n
s
t
a
t
e
d
n
u
m
b
e
r
o
f
l
i
t
t
e
r
s
(
M
e
t
h
o
d
s
s
t
a
t
e
2
p
u
p
s
/
s
e
x
/
l
i
t
t
e
r
)
L
i
t
t
e
r
i
s
n
o
t
u
n
i
t
N
u
m
b
e
r
o
f
s
q
u
a
r
e
s
c
r
o
s
s
e
d
M
0
F
0
R
e
a
r
i
n
g
M
0
F
0
S
e
l
f
-
g
r
o
o
m
i
n
g
M
0
F
0
P
N
D
3
0
S
a
m
e
a
s
f
o
r
P
N
D
2
1
N
u
m
b
e
r
o
f
s
q
u
a
r
e
s
c
r
o
s
s
e
d
M
0
F
0
R
e
a
r
i
n
g
M
↑
F
0
S
e
l
f
-
g
r
o
o
m
i
n
g
M
0
F
0
a
H
a
b
i
t
u
a
t
i
o
n
r
e
s
u
l
t
s
r
e
p
o
r
t
e
d
f
o
r
s
p
e
c
i
ﬁ
c
d
o
s
e
l
e
v
e
l
i
f
a
u
t
h
o
r
s
i
n
d
i
c
a
t
e
d
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
ﬁ
c
a
n
t
p
o
s
t
-
h
o
c
i
n
t
e
r
s
e
s
s
i
o
n
d
i
f
f
e
r
e
n
c
e
s
f
o
l
l
o
w
i
n
g
s
i
g
n
i
ﬁ
c
a
n
t
d
o
s
e
x
t
i
m
e
i
n
t
e
r
a
c
t
i
o
n
f
o
r
t
h
e
h
a
b
i
t
u
a
t
i
o
n
c
u
r
v
e
.
O
t
h
e
r
w
i
s
e
,
s
e
e
f
o
o
t
n
o
t
e
“
d
”
b
L
i
n
e
a
r
t
r
e
n
d
o
f
h
a
b
i
t
u
a
t
i
o
n
w
a
s
d
e
s
c
r
i
b
e
d
b
y
a
u
t
h
o
r
s
a
s
“
s
l
o
p
e
o
f
d
e
c
r
e
a
s
e
i
n
a
c
t
i
v
i
t
y
o
v
e
r
c
o
n
s
e
c
u
t
i
v
e
5
-
m
i
n
u
t
e
b
l
o
c
k
”
s
o
t
h
a
t
↑
s
l
o
p
e
c
o
u
l
d
i
n
d
i
c
a
t
e
l
e
s
s
h
a
b
i
t
u
a
t
i
o
n
o
r
i
n
c
r
e
a
s
e
d
a
c
t
i
v
i
t
y
t
o
w
a
r
d
s
e
n
d
o
f
s
e
s
s
i
o
n
.
d

i
n
d
i
c
a
t
e
s
a
s
i
g
n
i
ﬁ
c
a
n
t
i
n
t
e
r
a
c
t
i
o
n
b
e
t
w
e
e
n
d
o
s
e
a
n
d
5
-
m
i
n
i
n
t
e
r
v
a
l
s
,
b
u
t
n
o
p
o
s
t
-
h
o
c
g
r
o
u
p
d
i
f
f
e
r
e
n
c
e
s
r
e
p
o
r
t
e
d
.
∗
I
f
s
t
a
t
i
s
t
i
c
a
l
a
n
a
l
y
s
e
s
o
r
m
e
a
s
u
r
e
s
w
e
r
e
d
e
s
c
r
i
b
e
d
i
n
m
e
t
h
o
d
s
,
t
h
e
n
i
t
w
a
s
i
n
c
l
u
d
e
d
a
n
d
l
i
s
t
e
d
a
s
“
0
”
i
f
n
o
t
r
e
p
o
r
t
e
d
t
o
b
e
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
ﬁ
c
a
n
t
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M
o
t
o
r
a
c
t
i
v
i
t
y
i
n
t
h
e
M
O
U
S
E
(
o
r
a
l
o
r
s
c
)
A
u
t
h
o
r
T
e
s
t
A
g
e
a
n
d
R
o
u
t
e
o
f
E
x
p
o
s
u
r
e
A
g
e
T
e
s
t
i
n
g
S
a
m
p
l
e
S
i
z
e
p
e
r
D
o
s
e
L
e
v
e
l
(
Y
e
s
/
N
o
L
i
t
t
e
r
i
s
U
n
i
t
)
M
e
a
s
u
r
e
∗
M
a
g
n
i
t
u
d
e
o
f
D
o
s
e
T
e
s
t
e
d
,
m
g
/
k
g
-
d
a
y
D
o
s
e
t
o
d
a
m
s
0
.
2
1
5
B
r
a
q
u
e
n
i
e
r
e
t
a
l
.
,
2
0
0
9
O
p
e
n
ﬁ
e
l
d
#
l
i
n
e
c
r
o
s
s
i
n
g
s
(
5
-
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on subjective measures of motor strength
and coordination that are related, but not
directly comparable to, tests of motor activ-
ity. This study exposed dams (5/dose group)
dermally to 1 dose level of 1 mg/kg-d CPF
in 70% ethanol and measured effects in
1 offspring/sex/litter when they were adults
(PND 90) on subjective motor function tests
that were conducted blind to treatment level.
There were no signiﬁcant effects on beam-walk
time or beam walking ability. However, there
was a reduction in rat’s fore-paw grip time
(gripping of a 5-mm-diameter wood dowel
held horizontally) in both males and females,
and a decrease in females but not males in the
angle at which the animal began to slip back-
ward as the incline plane was raised from an
initial horizontal position. Signiﬁcant increases
in female brain AChE were measured at PND
90. AChE was not measured at or soon after
the time of exposure. This study is limited by
testing only one dose level with a low num-
ber of animals. Therefore, these results need
to be considered preliminary results from a
pilot study that needs to be repeated using
a larger sample size, more dose levels, and
more objective measures of motor function and
strength.
In summary, the overall weight of evidence
suggests that there are no marked effects on
motor activity following oral or sc gestational
exposure to 1 mg/kg-d in rats or mice. Effects
reported at 5 or 6 mg/kg include both increases
and decreases in activity (Table 6). One der-
mal study that did not meet our standards
for sample size (<6 litters) and number of
dose levels (<2) reported effects on motor
function at 1 mg/kg-d CPF. As described in
detail earlier, these differences may be related
to differences in species, route of exposure,
vehicle, and duration and type of activity mea-
sures.
Postnatal exposures Carr et al. (2001)
dosed pups every other day from PND 1 to
21 in a small-scale gavage study (10 males
and 10 females from only 5 litters per dose
level; Table 6A). Although the sample size of
ﬁve litters did not meet our standards, this
study included three dose levels and measured
activity at several ages, allowing for evalua-
tion of dose-response and temporal patterns.
There was a consistent dose-related decrease
in open-ﬁeld activity in offspring on d 25 and
30, but not at earlier ages. There were no
marked effects on motor activity at 3 mg/kg,
but decreases in activity following staggered
dose regimen (every other day administration)
of 3 increasing to 6, and 3 to 6 to 12 mg/kg-d.
In contrast, with sc CPF doses in DMSO
to pups, Levin et al. (2001) reported a statis-
tically signiﬁcant decrease in linear trend of the
habituation data at 5 mg/kg (PND 11–14) but
not at 1 mg/kg (PND 1–4), which was inter-
preted as a reduction in habituation consis-
tent with an increase in activity (Table 6B).
However, there was no statistically signiﬁcant
main effect of CPF, and the statistics for the
CPF × Block interaction and post hoc tests for
each time block were not reported. In compar-
ing the CPF and control habituation curves, the
means and standard errors overlapped for all
but 2 (3rd and 12th) of twelve 5-min interses-
sion time blocks. Thus, there was no marked
effect of CPF on the pattern of habituation,
and the statistically signiﬁcant decrease in linear
slope function used to represent the scalloped-
shaped habituation curves is not considered an
adverse effect.
Studies by Ricceri et al. (2003; 2006) sug-
gest that CPF increases activity in mice follow-
ing postnatal sc exposures (Table 6C). Ricceri
et al. (2003) reported a rise in total distance
traveled at PND 25 following sc injections
of 1 and 3 mg/kg-d CPF in DMSO at PND
11–14 but not PND 1–4 exposures. The sta-
tistical signiﬁcance was based on analyses that
considered the individual pup and not the lit-
ter as the experimental unit, and was based on
“post hoc” t-tests that were conducted despite
lack of signiﬁcant main effect on the ANOVA
(Ricceri et al. 2003). In a subsequent study,
Ricceri et al. (2006) injected mice from PND
11 to 14 with 1 and 3 mg/kg-d CPF in peanut
oil. There was greater frequency of crossing
on PND 70 following PND 11–14 exposure
to 3 but not 1 mg/kg-d (litter was consid-
ered the experimental unit of analysis). Thus,
the increase in activity following sc injections150 A. A. LI ET AL.
of 1 mg/kg-d in DMSO was not replicated,
although this may be due to differences in vehi-
cle, age of testing, activity device, and statistical
methods.
In summary, postnatal exposures to CPF
dose levels above 3 mg/kg-d produced
increases or decreases in activity depending
on the species, method of measuring activity,
and route of exposure. There were no con-
sistent patterns of treatment-related effects on
motor activity following postnatal doses below
3m g /kg-d.
Novelty-Induced Activity, Plus Maze and
Chocolate Milk Consumption Overall, there
were no consistent patterns of effects on
novelty-induced activity (Table 7) and behav-
ior, or on activity in open arms and center area,
which is considered by some investigators to
be correlated with effects on “anxiety”-like or
“depressive” behavior.
Gestational exposures with or without
postnatal exposures Braquenier et al. (2010)
reported an increase in “anxiety” in female
mouse offspring (male mice were not tested)
after oral exposures of dams during gestation
and lactation to 1 mg/kg, but not to 0.2 or
5m g /kg (Table 7A), indicating lack of dose
response relationship. Speciﬁcally, oral doses of
1m g /kg decreased the time spent in the open
arm of the elevated plus maze, without effects
on total number of arm entries (considered by
authors to reﬂect locomotor activity). In addi-
tion, oral exposure of CPF decreased time in
the center of the light side of the dark/light
box at 1 but not 5 mg/kg-d (Braquenier et al.
2010).
In contrast, Ricceri et al. (2006) found no
marked effects on time in open or closed arm in
male and female mice dosed orally in utero to
3o r6m g /kg (Table 7C), and found a decrease
in the number of head-dips in males only at
3 but not 6 mg/kg-d. Icenogle et al. (2004) also
demonstrated no signiﬁcant change in the time
spent in the open arm versus the closed arm
in rat offspring exposed in utero from GD 9 to
12 to sc injections of 1 or 5 mg/kg-d CPF in
DMSO (Table 7B).
The conﬂicting results may be due to dif-
ferences in duration of exposure and age of
testing or species. Nevertheless, these studies
do not support a consistent dose-related pat-
tern of effect on activity level on plus maze or
on behaviors potentially related to “anxiety.”
Postnatal exposures Ricceri et al. (2006)
reported a statistically signiﬁcant increase in
time spent in the open arms in female
mice injected sc with 3, but not 1 mg/kg-d
(Table 7C). There were no marked effects in
male mice, and there were no effects on num-
ber of center crosses following sc injections of
1o r3m g /kg from PND 11 to 14 (Table 7C).
Ricceri et al. (2006) considered these ﬁndings
as a reduction in “anxiety responses” consis-
tent with sex-selective effects reported in rats
by Aldridge et al. (2005).
Aldridge et al. (2005a) reported that PND
1–4 sc exposure to CPF increased time in open
arms and number of center crosses in male
but not female rats at 1 mg/kg (Table 7B),
the only dose level tested. Although “sex-
selective,” the effects were in the opposite sex
from that reported by Ricceri et al. (2006).
Furthermore, the males in the 1-mg/kg-d CPF
treated group from the Aldridge et al. (2005a)
study spent approximately 17% of time in open
arms, which is comparable to control animals
from 2 other studies reported by this labo-
ratory using identical procedures and age of
testing (PND 50–56). Speciﬁcally, Roegge et al.
(2008) found that control males and females
spent approximately 21 and 23% time in the
open ﬁeld, respectively. Timofeeva et al. (2008)
observed approximately 16% of time in open
arms for males and females combined. In con-
trast, Aldridge et al. (2005a) reported that the
concurrent control males and females spent,
respectively, 3 and 20% of time in open arms.
The control data from all three studies indicate
that there are no consistent sex-speciﬁc differ-
ences between male and female control rats,
and a wide range of control male values.
In general, the statistically signiﬁcant mea-
sures of automated novelty test resulted in no
marked effects on novelty preference follow-
ing sc injections of 3 mg/kg (1 mg/kg not
tested) for PND 1–4 or PND 11–14 (Ricceri
et al. 2003; Table 7C). The only effects were
statistically signiﬁcant increases in activity atT
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3m g /kg-d (the only dose level tested) during
one of the 5-min time bins after the mice were
exposed to the novel environment. However,
similar changes in motor activity were not seen,
especially during the beginning of the sessions,
when the activity device is a novel environment
to the animals (Table 6).
Aldridge et al. (2005a) reported effects of
PND 1–4 sc injection of 1 mg/kg-d CPF on
the consumption of chocolate milk compared
to water in both male and female rats tested
at PND 54. The control male and female rats
in this study clearly demonstrated a preference
for chocolate milk compared to water with
chocolate milk to water consumption ratios of
approximately 4.5 and 5.3, respectively. The
CPF-treated male and female rats had choco-
late milk–water preference ratios of approx-
imately 3.5, which was lower than for the
concurrent control but higher than for controls
from other studies by this laboratory (all non-
CPF studies) reporting milk–water preference
ratios of approximately 1.2–1.75 (Roegge et al.
2008; Timofeeva et al. 2008). The lack of dose-
response data and wide range of control values
indicate that this ﬁnding is not appropriate for
risk assessment purposes.
The apparent CPF effect on chocolate milk
consumption and increased time spent in the
open arm was described as “changes in 5HT-
related behaviors that resemble animal models
of depression,” citing papers using an olfactory
bulbectomized (OB) animal model of depres-
sion (Aldridge et al. 2005a). However, Kelly
et al. (1997) and Mar et al. (2000) caution that
the data generated using the OB model cannot
be attributed to any particular neurotransmit-
ter system. In addition, Slotkin et al. (1999)
previously found no effects on chocolate milk
consumption in young adult OB rats (13 wk
old), an age commonly used for this model of
depression (Kelly et al. 1997).
In summary, there are no consistent pat-
terns of adverse effect on novelty-induced
activity, plus maze (Table 7), and chocolate milk
consumption at any dose level, especially at
1m g /kg-d.
Spontaneous Alternation Spontaneous
alternation (Table 8) was measured by Levin
et al. (2001; 2002) and Icenogle et al. (2004)
using a T-maze without any positive or negative
reinforcement. There was a consistent lack of
effect on spontaneous alternation, the primary
endpoint for this test, following sc (DMSO)
gestational exposures to the dam or postnatal
exposures to the pups. Levin et al. (2002)
found a 3- to 5-s decrease in latency in the ﬁrst
of 5 trials following gestational exposures to
1a n d5m g /kg-d CPF. This effect was consid-
ered evidence of hyperactivity. However, there
was no evidence of increased activity in the
Figure-8 maze motor activity tests, as discussed
previously. The biological signiﬁcance of this
decrease in 3- to 5-s latency is uncertain, and
there was no consequence to the animals for
the time it took to perform the test.
Learning and Memory
Gestation exposures with or without
postnatal exposure Maurissen et al. (2000),
Icenogle et al. (2004), and Levin et al. (2002)
evaluated the effects of CPF gestational expo-
sures on learning and memory of offspring
(Table 9). Maurissen et al. (2000) dosed rat
dams by gavage with corn oil throughout
gestation and early lactation, and tested the
same 1 pup/litter from 18 litters/dose group
on a T-maze delayed spatial alternation test at
weaning and as adults (Table 9A). There were
no signiﬁcant effects on learning or retention
at dose levels of 0.3, 1, or 5 mg/kg-d at PND
22–24 or on long-term memory and retention
at PND 61–90. Icenogle et al. (2004) and Levin
et al. (2002) injected dams with 1 and 5 mg
CPF/kg-d sc in DMSO and tested the offspring
using a radial arm maze (RAM), with 12 of
16 arms baited to assess working memory and
4 arms unbaited to test reference memory
(Table 9B).
Icenogle et al. (2004) reported increased
errors at 5 but not 1 mg/kg-d following expo-
sures to dams from GD 9 to 12 (Table 9B).
The increased number of errors at 5 mg/kg-d
occurred in the ﬁrst and third block of trials out
of 6 for working memory, and only in the ﬁrst
block for reference memory. In contrast, Levin
et al. (2002) found that GD 17–20 exposures to
dams resulted in increased working and refer-
ence memory errors in female offspring at 1 butT
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b
l
i
n
d
G
D
1
7
–
2
0
s
.
c
.
D
M
S
O
W
k
4
–
6
1
0
M
+
1
0
F
;
1
0
l
i
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l
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i
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i
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u
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b
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↓
T
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e
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b
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h
e
r
e
w
a
s
1
r
a
t
/
s
e
x
/
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i
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l
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P
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p
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b
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i
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b
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e
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/
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↑
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u
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l
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d
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i
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/
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l
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r
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i
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u
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p
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u
n
i
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r
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d
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l
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i
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p
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i
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r
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N
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i
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r
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f
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i
t
t
e
r
i
s
u
n
i
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e
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u
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i
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u
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i
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i
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u
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a
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i
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i
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↓
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i
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e
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i
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i
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u
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not 5 mg/kg-d, and considered these ﬁndings
to be “sex-selective effects on behavioral devel-
opment.” Levin et al. (2002) speculated that,
at a higher dose level of 5 mg/kg, “cholinergic
actions may serve to offset adverse, non-
cholinergic effects on brain development.”
Another possibility not discussed by Levin
et al. (2002) is that the concurrent control
females could have an unusually low number
of errors based on comparison with two other
studies from the same laboratory (Aldridge et al.
2005a; Levin et al. 2001). In these two other
studies, Levin et al. (2001) and Aldridge et al.
(2005a) reported that control females normally
have higher errors than males, and that in these
studies CPF disrupted the normal sex differ-
ences in activity so that males and females
had the same activity level. In fact, the higher
number of female errors compared to male
errors at the 1 mg/kg-d dose level in Levin
et al. (2002) is consistent with the sex dif-
ferences in control animals observed in these
two other studies from the same laboratory
(Levin et al. 2001; Aldridge et al. 2005a).
Thus, the non-monotonic rise in error in the
1-mg/kg-d GD 17–20 females in Levin et al.
(2002) may be more a reﬂection of variabil-
ity in control female behavior than an effect
of CPF.
Billauer-Haimovitch et al. (2009) used a
Morris Water Maze to study effects of sc injec-
tion of CPF to mice during GD 9–18 (Table 9C).
Statistical signiﬁcant increases in latency were
measured at 1 and 3 mg/k g - db u tn o ta t5o r
10 mg/kg-d. Billiauer-Haimovitch et al. (2009)
indicated that there was an overall signiﬁcant
CPF effect, based on ANOVA, which was
“individually signiﬁcant at 1 and 3 mg/kg-d.”
However, the results of the Tukey tests for post
hoc analysis mentioned in the methods section
were not reported. Based on inspection of the
ﬁgure, there was overlap of the learning curves
f o rt h ec o n t r o l s ,1 ,5 ,a n d1 0m g /kg-d for the
ﬁrst 3 d, with the largest difference between
the controls and the 1-mg/kg-d group on the
fourth and last day estimated to be 3–4 s.
Thus, this study does not provide evidence of
a treatment-related effect of CPF.
Haviland et al. (2010) tested mice on
an 8-arm (6 baited, 2 unbaited) RAM and
a “novel” foraging food maze test (modiﬁca-
tion of RAM) following sc injection of CPF at
1o r5m g /kg-d in DMSO from GD 17 to 20
(Table 9C). CPF did not affect learning on the
traditional RAM, but these data may be unreli-
able because the controls did not learn on this
maze. Based on the results of the “novel” maze
test, CPF diminished foraging food recognition
learning in females (dose-dependent effects
a t1a n d5m g /kg/d) and enhanced forag-
i n gl e a r n i n gi nm a l e s( 1b u tn o t5m g /kg-d)
(Table 9C). Haviland et al. (2010) provided
inadequate information on methods (Table 9c).
The statistical analysis of the behavior was
described as a “mixed procedure accounting
for autocorrelation of repeated measures.” If
this refers to the repeated-measures ANOVA
as recommended by Holson et al. (2008), the
statistical signiﬁcances for the main effect and
interaction were not provided. Given the limi-
tations of this study and the novelty of the test
procedure, this study provides preliminary evi-
dence of effect of in utero exposure on learning
in female but not male offspring.
In summary, there are mixed results on
learning and memory tests following CPF expo-
sures during gestation. The differences could be
due to differences in species, route of expo-
sure, vehicle, age of exposure, time of test-
ing, and the behavioral test. However, based
on detailed evaluation of the methods and
results, examination of dose-response relation-
ships, and consideration of historical control
data, the overall weight of evidence does not
support a consistent pattern of effects on learn-
ing and memory across studies at 1 mg/kg-d.
Postnatal exposures Aldridge et al.
(2005a) and Levin et al. (2001) reported
that performance on the RAM in females
improved, and males exerted either no effect
or a deﬁcit in performance following sc
injection of 1 mg/kg CPF in DMSO to pups
from PND 1–4 (Table 9B). Thus, a decrease
in female error rate (improved performance)
was replicated in two separate studies by the
same laboratory and was considered to be
evidence that CPF disrupts sexually dimorphic
behaviors by improving female performance to
be comparable to that of the males (Aldridge
et al. 2005a; Levin et al. 2001). No marked162 A. A. LI ET AL.
effects were reported following sc injection of
5m g /kg CPF in DMSO from PND 11 to 14
(Levin et al. 2001).
Johnson et al. (2009) dosed CPF daily
with incrementally increasing oral doses from
PND1 to 21 (Table 9A). The lowest dose level
was 1 mg/kg from PND1 to 21, the mid-dose
level incrementally elevated doses from 1 to
2t o4m g /kg, and the highest dose level incre-
mentally rising doses from 1.5 to 3 to 6 mg/kg.
Beginning on PND 36, working and refer-
ence memory were tested using a radial maze.
In females, decreased errors (improved perfor-
mance) were observed in reference memory
at the mid- and high-dose levels, but there
were no marked effects on working memory.
In males, there were increased overall errors in
working and reference memory at the highest
dose. Johnson et al. (2009) reported statisti-
cally signiﬁcant increases in working memory
errors during the fourth week but not in the ﬁrst
3 wk of testing at the low and mid doses. These
effects do not appear to be adverse effects
because of the small differences in number of
errors (3.2 [low] to 3.3 [mid] errors vs. 2.7
[control] errors), and the lack of a consistent
dose-response pattern over the 4-wk period.
Statistically signiﬁcant hippocampal AChE inhi-
bition was measured in all treatment groups at
PND 20. AChE inhibition persisted in the mid-
and high-dose groups for up to 19 d following
exposure.
An increase in escape latency (deﬁcit in
performance) was measured in rats (males and
females combined) tested from PND 24 to
28 by Jett et al. (2001) on the Morris Water
Maze test following sc doses of 0.3 (d 1 only)
and 7 mg/kg in peanut oil on PND 7, 11, and
15 (Table 9B). Although not meeting our inclu-
sion criteria for studies because animals were
dosed after weaning, a signiﬁcant increase in
latency was also measured from PND 24 to
28 following sc doses of 0.3 and 7 mg/kg
on PND 22 and 26. This study was limited
because pups from only two to four recon-
stituted litters/dose level were used, with all
pups from the same litter dosed with the same
dose level. Finally, only 60% of control animals
were able to meet the criterion on this test.
It is notable that AChE levels were measured
3 h after injections, but no brain AChE inhibi-
tion was measured at 7 mg/kg, a dose level
that should have resulted in signiﬁcant AChE
inhibition. Taking all these factors into consid-
eration, this study is not sufﬁciently reliable for
risk assessment purposes.
Ricceri et al. (2003) tested effects of postna-
tal sc injections of CPF in DMSO to mice during
PND 1–4 or PND 11–14 (Table 9C), and found
no signiﬁcant effects on passive avoidance at
1o r3m g /kg-d (data were not shown).
In summary, a decrease in errors in females
(improvement in learning and memory) and
a tendency toward increased errors in males
were noted in two postnatal exposure studies
following sc injection of 1 mg/kg-d CPF (only
dose tested) (Aldridge et al. 2005a; Levin et al.
2001). Johnson et al. (2009) measured similar
effects at higher oral dose levels (incremen-
tal oral doses spanning from 1 to 4 or 1 to
6m g /kg-d) inducing 50% AChE inhibition in
the hippocampus, but did not observe effects
at 1 mg/kg.
Pharmacologic Challenge Pharmaco-
logic challenge studies (Table 10) were con-
ducted to determine whether CPF changes
the involvement of underlying neurotransmit-
ter systems that support different behaviors.
Many of the studies were conducted in
rats injected sc with CPF (Table 10B). CPF
attenuated the effects of scopolamine (mus-
carinic antagonist) to elevate the number
of errors on the RAM following gestational
(Icenogle et al. 2004; Levin et al. 2002) or
PND 11–14 exposures (Levin et al. 2001),
but not PND 1–4 exposures (Table 10B;
Levin et al. 2001). In comparing the effects
of scopolamine across the different studies, it
appears that the variability in the data is high,
and scopolamine did not consistently produce
dose-response increase in number of errors
in controls (Levin et al. 2001, Fig 4; 2002,
Figures 5, 6, and 7). Ketanserin elevated the
number of errors on the RAM with increasing
doses of ketanserin in animals treated with
1m g /kg-d of CPF from PND 1–4 (Aldridge
et al. 2005a). These same doses of ketanserin
exerted no marked effect on saline-treatedT
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animals, similar to that observed by Levin et al.
(2005). Ketanserin is a potent 5HT2 receptor
antagonist, but also has effects on other 5HT,
α-adrenergic, and histamine receptors (Levin
et al. 2005). These data support hypotheses
requiring further testing that CPF produces
alterations in cholinergic, serotonergic, and/or
other neuropharmacologic systems that are
unmasked by pharmacologic challenge.
One oral study was conducted by Venerosi
et al. (2010) in mice gavaged with a single
dose level (6 mg/kg-d) of CPF during ges-
tation (Table 10A). Attenuation of the effect
of a single 40-mg/kg ip dose of ﬂuvoxamine
(5HT uptake inhibitor) to increase swimming
duration or frequency (i.e., number of swim-
ming intervals) on a forced swim test was
measured following 6-mg/kg CPF exposure
during gestation. Enhanced swimming dura-
tion or frequency in controls was interpreted
as less “depressive-like” behavior in controls.
Fluvoxamine also reduced duration of mater-
nal aggression while in the nest. The baseline
behavior (i.e., response following acute vehi-
cle for ﬂuvoxamine) of CPF and control ani-
mals was different for several forced swimming
and maternal aggression parameters, making it
more challenging to interpret the ﬂuvoxamine
effects. Venerosi et al. (2010) speculated that
the acute effects of ﬂuvoxamine are due to
either “changes in constitutive 5HT levels or
overactivation/ hypoactivation of speciﬁc 5-HT
receptor families,” yet no neuropharmacologic
evaluations were conducted.
In summary, these data form the basis
for developing hypotheses for further testing.
Further testing needs to include concurrent
measurements of neuropharmacologic end-
points based on clearly deﬁned hypothesis. The
pharmacologic challenge data need to be repli-
cated using multiple doses of CPF, using an oral
route of exposure, and avoiding DMSO as the
vehicle.
Social and Agonistic Behaviors
Four studies measured multiple param-
eters for many social agonistic or mater-
nal behaviors in adolescent or adult mice
exposed during gestation and/or prior to wean-
ing (Ricceri et al. 2003,2006; Venerosi et al.
2006, 2008).
Venerosi et al. (2006) measured USV and
frequency and duration of different social
recognition behaviors in female offspring. This
study exposed pups prenatally (GD 15–18; 0,
3, or 6 mg/kg) and postnatally (PND 11–14,
0, 1, or 3 mg/kg), resulting in nine different
groups, each dosed with one combination of
gestational and postnatal oral doses. Of 9 pos-
sible dose combinations, the only statistically
signiﬁcant effect was (1) an increase in USV
by female adult mouse during social interac-
tion with another female mouse and (2) a
rise in the frequency of social investigation in
mice exposed gestationally to 6 mg/kg and
postnatally to vehicle. The lack of effects in
mice exposed gestationally to 6 mg/kg and
postnatally to 1 or 3 mg/kg indicates a lack
of dose-response relationship. The biological
function of the USV emission by the female
mouse during social interaction with another
female is “poorly understood” (Venerosi et al.
2006). Thus, further research and replication
of ﬁndings are needed before these data may
be considered relevant for human health risk
assessment.
A similar study by Ricceri et al. (2006) also
involved nine combinations of the same doses,
except that postnatal sc (not oral) injections
were used. Ricceri et al. (2006) found that
1a n d3m g /kg (PND 11–14) CPF enhanced
maternal-like behaviors in “virgin females”
exposed to pups from different mothers. This is
an unreliable effect, given the artiﬁcial condi-
tions of the test and the fact that there were no
effects on latency, frequency, and duration of
nest building and number of pups retrieved to
the nest. The relevance of these data to human
health risk assessment is questionable.
Venerosi et al. (2008) exposed mice from
P N D1 1t o1 4t oas i n g l es cd o s eo f3m g /kg-d
in peanut oil. Measures of sociability, nest-
building activity, and maternal behavior were
analyzed in dams. The main ﬁnding was
that females showed alterations in different
aspects of the maternal behavior repertoire
following artiﬁcial conditions of repeated dailyCHLORPYRIFOS DEVELOPMENTAL NEUROBEHAVIORAL OUTCOMES 167
removal of nest and pups. These were alter-
ations on individual parameters, and a large
number of key maternal behaviors were unaf-
fected (Venerosi et al. 2008). For example,
latency to ﬁrst licking episode on postpartum
day 1 and latency to start nest building was
lower at 3 mg/kg. However, there was no
signiﬁcant effect on quantitative or qualitative
nest features, or on licking durations and fre-
quencies. Decreased combined time crouching
and nursing (an apparent a posteriori analy-
sis) was measured, but no marked differences
were found in the frequencies, latencies, or
durations of the other pup-directed behaviors
such as retrieving, snifﬁng, and nest build-
ing. There were also no signiﬁcant effects on
social behavior and social preferences at ado-
lescence. Taken together, there appears to be
a low level of concern for the patterns of alter-
ations measured in mice dosed postnatally with
3m g /kg-d.
Ricceri et al. (2003) studied the effects of
postnatal injections of 1 and 3 mg/kg-d CPF
sc in DMSO. Both doses were used for PND
1–4 and PND 11–14 exposure periods. For
PND 1–4 exposures, frequency of aggressive
grooming increased at 3 but not 1 mg/kg-
day, although the main effect of treatment was
not statistically signiﬁcant. For PND 11–14,
male agonistic responses appeared signiﬁcantly
enhanced throughout the test period after both
doses of CPF. The agonistic responses included
aggressive, defensive, and submissive behav-
iors. Therefore, conclusions regarding aggres-
sive behaviors speciﬁcally require further anal-
yses of data that were not presented. However,
these results are consistent with enhanced
agonistic behaviors reported by Ricceri et al.
(2006) at 3 mg/kg-d CPF sc in peanut oil, as
described next.
In the Ricceri et al. (2006) study, the fre-
quency and duration of six male agonistic
behavior parameters were analyzed following
GD 15–18 gavage and/or PND 11–14 sc injec-
tions of CPF in peanut oil. Following prenatal
injections, a signiﬁcant increase in offensive
posture frequency at 6 but not 3 mg/kg/dw a s
found. For postnatal injections, a signiﬁcant rise
in frequency and duration of attack duration at
3 but not 1 mg/kg-d. However, this signiﬁcant
elevation in frequency was based on post-
hoc comparisons conducted in the absence
of signiﬁcant main effect on the ANOVA. The
duration and incidence of these ﬁndings at 3
mg/kg-d was, respectively, 6 versus 2.5 (treated
vs. control) s of attack response per 5 min and
3.5 versus 2 attacks per 5 min. It is noteworthy
that no effects on aggressive or agonistic behav-
iors were reported at 1 mg/kg-d when peanut
oil was used instead of DMSO as the vehicle
(Ricceri et al. 2006 compare with Ricceri et al.
2003).
In summary, multiple social behavior
parameters were measured, and the frequency
and duration for each of these parameters
were statistically analyzed. The guidance from
the U.S. EPA Neurotoxicity Risk Assessment
Guidelines to risk assessors on similar type of
observational data involving a large number
of endpoints (i.e., functional observational bat-
tery) applies when considering these data for
risk assessment purposes (U.S. EPA 1998b). The
relevance of statistically signiﬁcant test results
needs to be evaluated according to “the num-
ber of signs affected, the dose(s) at which
effects are observed, and the nature, severity
and persistence of the effects and their inci-
dence in relation to control animals” (U.S. EPA
1998b).
Taking into account the overall patterns of
perturbations of behavioral parameters related
to social behaviors, the magnitude of change
or low incidence of the behaviors, and the
number of multiple comparisons statistically
analyzed, the biological signiﬁcance of these
alterations in social behaviors to humans is
uncertain. Based on the data thus far, 1 mg/kg-
day appears to be a no-observed-adverse-
effect level (NOAEL) for perturbations in mouse
social, agonistic and maternal behaviors.
Ricceri et al. (2006) measured brain and
serum cholinesterase (ChE) activity in offspring
at PND 15 after oral exposure from GD 15–
18 and/or sc injections from PND 11–14. The
mice were sacriﬁced 24 hr after postnatal expo-
sures, and more than 15 d after last CPF
injection for mice receiving only prenatal CPF
exposures. There was a 20–50% decrease in168 A. A. LI ET AL.
serum BuChE activity in all groups dosed post-
natally with either 1 or 3 mg/kg-d. As expected,
there was no brain or serum ChE inhibition in
PND 15 pups dosed prenatally with vehicle,
3o r6m g /kg-d, and postnatally with vehicle.
Ricceri et al. (2003) reported signiﬁcant pup
brain AChE inhibition 1 hr following PND 1–
4 (but not PND 11–14) sc doses of 1 and
3m g /kg-d. In contrast to the large number
of rat studies conducted by multiple labora-
tories at more optimal sacriﬁce times (2–6 hr)
after exposure, RBC and brain AChE inhibition
has not been adequately characterized in mice
following CPF exposures. From a risk assess-
ment standpoint, 1 mg/kg-d is an effect level
for RBC or brain AChE inhibition or plasma
BuChE following postnatal exposures to mice
or rats. Thus, behavioral perturbations reported
in mice exposed to 1–6 mg/kg-d occurred
at dose levels considered to be effect levels
for CPF based on serum, RBC or brain ChE
inhibition.
Neuropharmacologic Endpoints
Many studies evaluated the effects of ges-
tational and/or postnatal exposures of CPF
on the cholinergic and other neurotransmit-
ter systems. Although the emphasis of this
review is on neurobehavioral effects, under-
standing potential MOA is important in deter-
mining whether the most sensitive endpoints
are being used for risk assessment and in under-
standing the weight of evidence relevant to
neurobehavioral outcomes.
Cholinergic Effects The cholinergic sys-
tem plays an important role in brain develop-
ment beginning during the embryonic period
and continuing into the postnatal period
(Brimijoin and Koenigsberger 1999; Lauder
and Schambra 1999). Therefore, inhibition
of AChE during development by CPF expo-
sure may have the potential to produce alter-
ations in neuronal development. Alterations in
cholinergic endpoints such as choline acetyl
transferase (ChAT), mAChR, high-afﬁnity presy-
naptic choline transporter (HAChT), vesicular
Ach transporter (VAChT), and choline trans-
porters were found (Chakraborti et al. 1993;
Chambers 2003; 2004; 2005; Qiao et al.
2002; 2003; 2004; Richardson and Slotkin
et al. 2001; Tang et al. 1999; Zhang et al.
2002). Although alterations in some of these
cholinergic parameters were more persistent
than AChE inhibition, the signiﬁcance of these
neuropharmacologic alterations (some less than
20% at lower doses) in terms of causal
relationship with functional effects has not
been established (Carr et al. 2001; Guo-Ross
et al. 2007; Richardson and Chambers 2005).
Nevertheless, decreases in mAChR binding (as
measured by maximal binding sites Bmax)a n d
HAChT (as measured by 3H-hemicholonium-
3 binding) were considered to be among the
more sensitive mechanistic endpoints that may
potentially result in alterations in neurologic
functions.
Richardson and Chambers (2003; 2004;
2005) measured effects of CPF on cholinergic
neurochemistry, including brain AChE inhibi-
tion, mAChR, HAChT, VAChT, and ChAT. These
studies indicated that gestational exposure to
7 but not 3 or 1 mg/kg-d CPF results in
long-term (e.g., 1 mo) alterations of presynap-
tic cholinergic endpoints at a time when brain
AChE inhibition had returned to control lev-
els. Richardson and Chambers (2005) dosed
pups from PND 1 to 21 by gavage (corn oil)
with a low dose, 1.5 mg/kg-d, and high dose,
1.5 mg/kg, increasing to 3 and then 6 mg/kg.
Both dosage levels resulted in persistent inhibi-
tion of AChE and alterations in mAChR density
and reductions in presynaptic cholinergic end-
points.
One dermal study by Abdel-Rahman et al.,
(2004) found no marked effects on ligand-
binding densities of nicotinic and mAChRs in
cortex at PND 60 in offspring of dams exposed
dermally to 0.1 mg/kg-d CPF in ethanol.
Increases in AChE activity (not inhibition) were
found in midbrain regions in males and brain-
stem regions in females, while other brain
regions in both sexes showed no signiﬁcant
effect. AChE activity was not measured during
or soon after the period of exposure.
Slotkin et al. (2001) and Qiao et al. (2002;
2003; 2004) measured ability of CPF to alter
cholinergic endpoints such as ChAT, HAChTCHLORPYRIFOS DEVELOPMENTAL NEUROBEHAVIORAL OUTCOMES 169
and mAChR following exposures to dams dur-
ing GD 9–12 or GD 17–20, or directly to pups
on PND 1–4 or PND 11–14. A large number of
measures were analyzed in males and females
at different ages and multiple brain areas. There
were some alterations (mostly decreases) in
HAChT binding, ChAT activity, and mAChR
binding at doses of 1 or 5 mg/kg-d following
gestational and/or postnatal exposures. Song
et al. (1997) and Qiao et al. (2002) measured
rat pup brain AChE inhibition 24 h after the
last sc injections of CPF in DMSO. Brain AChE
inhibition was measured in pups from dams
exposed for GD 17–20 to 5 mg/kg-d (>40%),
2m g /kg-d (around 20%), but not 1 mg/kg-d
(Qiao et al. 2002). Brain AChE inhibition (25%)
was measured in pups directly injected PND
1–4 with 1 mg/kg-d CPF (Song et al. 1997).
Even greater AChE inhibition (75%) was found
in pups sacriﬁced 2 h after the ﬁrst sc injec-
tion of 1 mg/kg CPF on PND 1 (Dam et al.
2000).
In general, brain AChE inhibition from
oral or sc in dams during gestation or pups
dosed postnatally is an equally or more sen-
sitive endpoint compared to other cholinergic
alterations measured in rat and mouse pups.
At present, the relationship between CPF
effects on cholinergic measures and behavioral
effects is not clearly understood.
Noncholinergic Neuropharmacologic
Effects Several studies reported that CPF pro-
duced long-lasting alterations of serotonergic,
dopaminergic, and possibly noradrenergic sys-
tems after gestational or postnatal sc injections
of 1 or 5 mg/kg-d (Aldridge et al. 2003; 2004;
2005b; 2005c; Dam et al. 1999; Raines et al.
2001; Slotkin et al. 2002; Slotkin and Seidler
2005; 2007a; 2007b [referred to as Slotkin et
al. lab]). These studies measured a number of
serotonergic endpoints, including 5HT1a and
5HT2 receptors, as well as 5HT transporter
(5HTT) binding in multiple brain regions at dif-
ferent ages. Noradrenergic and dopaminergic
endpoints were also measured, but in fewer
studies. Alterations occurred in different direc-
tions and magnitudes and include increasing,
decreasing or ﬂat dose-response relationships
depending on the speciﬁc parameter, age of
exposure, age of sacriﬁce, dose, and brain
regions (Slotkin et al. lab).
In general, these studies used 1
pup/sex/litter from 6 litters, 2 dose lev-
e l s( 1a n d5m g /kg in DMSO, sc) for the
gestational exposures (Aldridge et al. 2004;
2003; Slotkin and Seidler 2007b 2005b), and
only 1 dose level postnatally (1 mg/kg for PND
1–4, PND 2–5, and 5 mg/kg for PND 11–14;
Dam et al. 1999; Raines et al. 2001; Seidler
2005; 2007a; Slotkin and Aldridge et al.
2005b; 2005c; Slotkin et al. 2002). Limitations
regarding the sc route of exposure, DMSO as
the vehicle, and lack of dose-response data
need to be considered in evaluation of results
for risk assessment purposes. In addition,
caution is needed in interpreting the biological
signiﬁcance of these noncholinergic data due
to methodological issues described next.
Biological signiﬁcance of statistical signiﬁ-
cant pooled data require further evaluation of
speciﬁc measures A major challenge in eval-
uating consistency of results within and across
studies is that the statistical analyses were
based on data pooled together across multi-
ple brain regions, exposure durations, ages, and
neuropharmacologic endpoints (Slotkin et al.
lab). Lower order analyses (e.g., group com-
parisons) were conducted depending on which
interactions were statistically signiﬁcant. For
example, Aldridge et al. (2004) concluded
that exposure to a low dose of CPF (GD
9–12) “elicited a signiﬁcant overall elevation of
5HT1a, 5HT2 and 5HTT ligand binding with-
out statistical distinction by region, measure
or sex.” In other words the statistical signif-
icance was based on statistical analysis that
pooled together data for multiple 5HT recep-
tor ligands and brain regions and both sexes.
However, inspection of the graphed data indi-
cates that many of the changes in individual
measures in this and other studies (Slotkin
et al. lab) for each sex, period of exposure,
neuropharmacologic measure, and/or brain
region may be of questionable biological sig-
niﬁcance. Some of these individual effects that
were statistically signiﬁcant in the pooled anal-
yses are <10–20% alterations from control
and/or have large standard errors within 10%170 A. A. LI ET AL.
of the x axis representing 0 % change from
control.
Biological signiﬁcance of percent changes
require evaluation of control values Most of
the neuropharmacologic effects are reported
as percent changes. The statistical analysis was
based appropriately on the actual data, not
on percent differences from control (Slotkin
et al. lab). Control data were reported in some
but not all papers, or in nonstandard units of
measure (sometimes not corrected for protein
level or wet weight of the brain region), mak-
ing it more difﬁcult to assess the reliability of
measures.
If control levels are too small to measure
reliably, this may result in apparent large per-
cent differences from control. For example,
Aldridge et al., (2005b) reported a statistically
signiﬁcant 40–50% decrease in dopamine lev-
els in the hippocampus at PND 60 at 1 and
5m g /kg-d, with no changes in the striatum,
cortex, midbrain, or brainstem following ges-
tational exposure to CPF. However, the small
dopamine (DA) values for hippocampus in
controls raise doubts about the biological sig-
niﬁcance of the 40–50% changes from con-
trol. Indeed, in later publications, Slotkin et al.
(2002) state that DA levels were not measured
in the hippocampus, because they were con-
sidered too low to be reliable. Similarly, in
control animals, Dam et al. (1999) and Aldridge
et al. (2003) demonstrated that levels of several
cholinergic, noradrenergic, and DA endpoints
were low from GD 17 to PND 5 and then
rapidly rose (depending on brain area) from
PND 5 to PND 20. Thus, evaluation of bio-
logical signiﬁcance of percent changes from
control measured during these early periods
should take into consideration low control val-
ues and normal control variation (e.g., histor-
ical control values) during this period of rapid
change.
Receptor binding assays use subsaturating
ligand concentrations The serotonergic bind-
ing assays and the majority of those for
cholinergic binding for CPF were made with
single ligand concentrations that are at or
slightly above the Kd value and below full
saturation (Aldridge et al. 2005c). This is in
contrast to approaches used by Richardson and
Chambers (2004) for cholinergic endpoints, in
which a single saturating concentration was
used based on preliminary kinetic studies con-
ducted in the laboratory under identical exper-
imental conditions, or by Tang et al. (2003), in
which different concentrations of ligands were
used to calculate Kd and Bmax.
Although this method of using subsatu-
rating concentrations might be appropriate as
a screen in preliminary-hypothesis-generating
experiments, it is important to rigorously con-
ﬁrm that these alterations are biologically
meaningful by conducting a full kinetic exam-
ination or employing a sufﬁcient single con-
centration (i.e., 10 × Kd) that will allow for
an accurate estimation of Bmax. Thus, further
conﬁrmation is needed to ensure that reported
differences from control (<10–25%) are not
artifacts of the screening methods used.
Data are inadequate to establish MOA,
and risk assessments based on RBC AChE inhi-
bition are protective of non-AChE inhibition
effects At present, data support hypotheses
requiring further testing that there may be
alternative MOA for developmental neuro-
toxic effects other than brain AChE inhibi-
tion. For the reasons outlined earlier, data are
insufﬁcient to consider serotonergic or other
neuropharmacologic as a MOA for behavioral
or other developmental outcomes. In addition,
many of the neuropharmacologic changes stud-
ies did not measure AChE inhibition concur-
rently in the experiments. However, Song et al.
(1997) and Qiao et al. (2002) reported signif-
icant offspring brain AChE inhibition following
postnatal exposures to 1 mg/kg CPF (Table 11).
Maurissen et al. (2000) and Mattsson et al.
(2000) also found signiﬁcant inhibition of brain
and RBC AChE inhibition and of plasma BuChE
in dams following oral exposure to 0.3 or
1m g /kg CPF from GD 6 to 20. Therefore,
all effects reported at 1 mg/kg following ges-
tational or postnatal sc exposures occur at dose
levels that would be considered in risk assess-
ments to produce brain or RBC AChE or plasma
BuChE inhibition in pregnant dams or offspring.
Thus, it cannot be ruled out that these “non-
AChE inhibition” effects were a result of AChET
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inhibition that occurred daily during the period
of dosing.
This review focuses on neuro-
pharmacologic (e.g., serotonergic,
noradrenergic, dopaminergic) ﬁndings. Other
mechanistic in vitro and in vivo studies were
comprehensively reviewed by Eaton et al.
(2008). Eaton et al. (2008) conducted an
expert panel review of the in vitro and in
vivo mechanistic studies and concluded that
“the weight of evidence from animal studies
and in vitro mechanistic studies suggests that
many of the neurodevelopmental effects of
CPF are secondary to inhibition of AChE in
target tissues such as the developing brain,
although plausible alternative mechanisms
have been proposed, based on in vitro studies”
(102). The U.S. EPA (2011) recent preliminary
human health risk assessment of CPF stated
that “although multiple mechanisms have been
proposed, a coherent mode of action with
supportable key events, particularly with regard
to dose-response and temporal concordance,
has not yet been elucidated.”
From a risk assessment perspective, data
thus far indicate that these “non-AChE inhi-
bition” effects occur at doses that produced
RBC or brain AChE inhibition and/or plasma
BuChE inhibition in adults, dams, or offspring.
Although there is insufﬁcient evidence to deter-
mine whether neuropharmacologic effects rep-
resent different MOA, risk assessments based
on AChE inhibition are likely to be protective
of these potentially different cholinergic or
noncholinergic MOA.
Neuropathologic and Morphometric
Measurements
Although neuropathologic and
morphometric measurements are not a
focus of this review, the main ﬁndings are
brieﬂy discussed because they may provide
additional weight of evidence. There were one
oral gestation/lactation study (Maurissen et al.,
2000), three dermal gestational studies (Abdel-
Rahman et al., 2003; 2004; Abou-Donia et al.
2006); and two sc (DMSO) postnatal studies
(Roy et al., 2004; 2005) evaluating effects
of CPF on histopathology or morphometric
measures in the brain. With the exception of
the oral study by Maurissen et al. (2000), all
other studies tested only one dose level.
Brieﬂy, alterations in morphometric mea-
surements and other quantitative measures
(e.g., length, thickness, neuron and glial cell
counts) were found at 5 mg/kg-d following
either oral GD 6–PND 10 (Maurissen et al.
2000) or sc PND 11–14 exposures (Roy et al.
2004 2005). These effects occurred at doses
that are known to produce signiﬁcant brain
or RBC AChE and plasma BuChE inhibition
in the dams during gestation and >65% brain
AChE inhibition in pups following direct dos-
ing to pups (Table 11). In addition, Maurissen
et al. (2000) reported that 5 mg/kg-d produced
maternal toxicity such as decreased body-
weight gain and clinical signs of AChE inhibition
such as tremors. In the pups, this was accompa-
nied by an increase in mortality between PND
1 and 4 (1% in controls vs. 25% at 5 mg/kg-d),
and decreases in body and brain weight.
Since this article is focused on
neurobehavioral endpoints, it is of interest
that Roy et al. (2005) reported a number
of “subtle morphologic changes in the hip-
pocampus” including number of neurons and
glia, and neuronal cell diameter. The hip-
pocampus is related to learning and memory
function. These morphologic changes included
decreased layer thickness and neuron and
glial cell count in the hippocampus following
PND 11–14 sc injections of 5 mg/kg-d CPF.
Levin et al. (2001) also dosed rats from PND
11–14 with sc injections of 5 mg/kg-d CPF, and
found no effect on RAM working or reference
memory, but did not report any histopathology
examination of the hippocampus. Similarly,
Maurissen et al. (2000) observed no effects on
a delayed spatial alternation test of learning
and memory following GD 6–PND 10 mater-
nal doses of 0.3 to 5 mg/kg-d CPF, and no
morphometric effects on the hippocampus.
The differences in morphometric measure-
ments may be related to differences in the
types of brain measurements made and the
route and period of exposures. At present,
neuropathology data cannot be directly linked
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Decreases (approximately 12%) in num-
ber of surviving Purkinje cells and increases
(approximately 8%) in glial ﬁbrillary acidic
protein (GFAP) immunostaining in cerebellum
were also noted in offspring at 1 mg/kg-d
(Abou-Donia et al. 2006) but not 0.1 mg/kg-
d dermal exposures during gestation by the
same laboratory (Abdel-Rahman et al. 2003;
2004). The GFAP measures were based on
methods of approximating areas with targeted
levels of pixels from digitized images of GFAP
immunostained sections. In contrast, Garcia
et al. (2002) found no effects on GFAP levels
measured from brain homogenates following
doses of 1–10 mg/kg from GD 17 to 20. These
conﬂicting results may also be due to differ-
ences in duration and route of exposure, age
of sacriﬁce, and method of measuring GFAP
levels. The functional relevance of the ﬁnd-
ings from Abdel-Rahman et al. (2003; 2004)
remains unknown.
EVALUATION OF EPIDEMIOLOGY AND
ANIMAL NEUROBEHAVIORAL DATA
FOR RISK ASSESSMENT
The purpose of this review was to provide
in-depth analyses of CPF exposure and devel-
opmental neurobehavioral outcomes from the
published human and animal in vivo peer-
reviewed papers within the context of human
health risk assessment. Previous approaches
provided a summary of signiﬁcant ﬁndings
appropriate for comparisons of dose levels at
which potential adverse effects were reported.
In contrast, this review concentrated on pro-
viding a critical analysis of the neurobehavioral
studies for risk assessment purposes. An impor-
tant aspect of the approach used in reviewing
the data is that methods and results (absence
and presence of ﬁndings) were systematically
tabulated by dose level and period of expo-
sure. In addition, historical control data was
considered as an additional perspective.
In the animal studies, the lowest dose
level at which alterations in developmen-
tal neurobehavioral, neuropharmacologic,
and neuropathologic/morphometric end-
points have been reported more frequently
i s1m g /kg-d (1000 µg/kg-d). The weight
of evidence for neurobehavioral effects at
1m g /kg-d is not compelling when taking into
consideration dose response, study method-
ology, pattern of effects, and consideration
of both the absence and presence of ﬁnd-
ings from different studies. There were a
greater number of ﬁndings reported following
exposure to 3–6 mg/kg-d. Signiﬁcant RBC
or brain AChE inhibition either in dams or in
pups was produced at and below these dose
levels. Therefore, risk assessments based on
AChE inhibition are likely to be protective of
these behavioral effects. As discussed in the
introduction of this review, exposures to the
general population today are primarily dietary
in the 10−2 to 10−3 µg/kg-d dose level, which
is more than 5 orders of magnitude below the
animal dose levels. Estimates for daily exposure
to pregnant women and children following
previously allowed residential uses are in the
10−1 to 10−3 µg/kg-d dose range (Lowe
et al. 2009; Eaton et al. 2008). Estimates for
agricultural worker exposures are in the 101
µg/kg-d dose range.
Epidemiology studies are also considered
for use in risk assessment. However, the dose-
response data for CPF are not reliable for
human health risk assessment, largely because
of the paucity of exposure data available from
each study. Further, in the studies with multiple
sources of data (e.g., biomarker data and
air monitoring samples), correlations among
these measures were weak (r ∼ .2) (Whyatt
et al. 2005). Furthermore, while data from the
biomarkers of CPF at a single time point pro-
vide some indication of short-term exposure,
understanding long-term patterns of use could
add valuable information regarding exposures
within and across critical stages of develop-
ment in utero and after birth. In addition,
although measures of nonspeciﬁc metabolites
may be more objective quantitative measures
of exposure to OP in general as compared to
self-reported exposure information, such mea-
sures cannot form the basis for causal conclu-
sions about CPF or other speciﬁc chemicals.
At present, the epidemiology studies are useful
to consider for hazard characterization.174 A. A. LI ET AL.
Based on the epidemiologic studies
reviewed thus far, the evidence for causality
is weak. As new studies are published, there
are four important principles in evaluating the
CPF literature that are important to consider:
(1) relative strengths and limitations of the
studies, particularly in their ability to provide
informative data about associations between
CPF exposure and neurobehavioral and other
relevant outcomes, taking into account poten-
tial bias and with consideration of the evidence
for and against causality; (2) differences in
exposure settings across the studies (Needham
2005); (3) measurement and characterization
of exposure, keeping in mind that different
biomarkers have different degrees of speciﬁcity
with respect to CPF, and thus, a statistically
signiﬁcant result for DAPs and DMPs in the
absence of a similar ﬁnding for DEPs is not
likely to reﬂect exposure to CPF; and (4) weight
of evidence for biological plausibility needing
to be considered, rather than selecting individ-
ual ﬁndings from human studies and trying to
ﬁnd a “match” with animal data.
The conclusion of this review is that
there is insufﬁcient evidence that human
neurodevelopmental exposures to CPF result
in adverse neurobehavioral effects in infants
and children based on studies that estimated
CPF exposure using measures derived from
maternal or child urine, umbilical cord blood,
or personal air monitoring samples. In look-
ing for consistent patterns across studies, and
certainly across species, one needs to guard
against simply accumulating a list of positive,
statistically signiﬁcant, yet potentially random
ﬁndings. With this caveat in mind, two exam-
ples are discussed.
An increasing number of abnormal reﬂex
in newborn infants was the only one of seven
BNBAS domains that was found to be statis-
tically signiﬁcant in two epidemiologic studies
evaluating DEPs and DAPs in maternal urine
(Engel et al. 2007; Young et al. 2005). Young
et al. (2005) and Engel et al. (2007) relate
these outcomes to animal results such as signif-
icant alterations in cliff avoidance and righting
reﬂex at postnatal days 1 and 3 following sc
gestational exposures to 25 mg/kg-d reported
by Chanda and Pope (1996). The route of
exposure and dose level are not relevant to
humans. Dose levels of 5 and 25 mg/kg-d
produced greater than 60% brain AChE inhibi-
tion (Chanda and Pope 1996; Mattsson et al.
2000; Maurissen et al. 2000) and maternal
toxicity (Maurissen et al. 2000, Qiao et al.
2002). The overall weight of evidence indi-
cates that CPF does not exert effects on
neurodevelopmental landmarks and reﬂexes in
animals tested prior to weaning at doses below
5m g /kg-d (Table 5). Therefore, the conclusion
that these studies provide biological plausibil-
ity for abnormal reﬂexes in newborn humans is
not appropriate.
As a second example, one of the epidemi-
ology studies reported a statistically signiﬁcant
association (with wide 95% conﬁdence inter-
val) between cord blood CPF and maternal-
reported PDD problems at age 36 mo (Rauh
et al. 2006). Animal models can evaluate only
certain aspects of heterogeneous complex neu-
rologic disorders. At present, there are no
deﬁnitive animal behavioral models for PDD
or autism, and it is not appropriate to make
direct comparisons between speciﬁc behav-
ioral effects of CPF in animals with autism.
Furthermore, none of the epidemiologic studies
in this review were able to evaluate outcome
misclassiﬁcation by obtaining clinical conﬁrma-
tion information regarding PDD, ADHD, or
other behavioral problems or disorders mea-
sured by maternal reports on the CBCL.
CONCLUSIONS
This review evaluated the published
human epidemiology and animal litera-
ture that described potential associations
between CPF exposure and developmen-
tal neurobehavioral outcomes, emphasizing
their role in informing risk assessment. The
epidemiologic studies do not support a causal
association between CPF exposure to mothers
and adverse neurobehavioral outcomes in
infants or young children. Only one study
evaluated associations between potential child
(postnatal) CPF based on urine metabolitesCHLORPYRIFOS DEVELOPMENTAL NEUROBEHAVIORAL OUTCOMES 175
and neurobehavioral outcomes and similarly
did not provide strong evidence in support of
causality. These cohorts are being followed into
early and middle childhood, permitting further
evaluation.
Taking into consideration both oral and sc
animal behavioral studies, data indicate that
most of the alterations of neurobehavioral,
neuropharmacologic, or morphologic param-
eters occur at exposure levels that also pro-
duce brain or RBC AChE or plasma BuChE
inhibition in adults or pups. Based on ani-
mal studies reviewed in this article, the no-
observed-effect level (NOEL) for RBC AChE
inhibition is <0.3 mg/kg-d following gesta-
tional exposures to pregnant rats. The U.S.
EPA estimated a BMDL10 of 0.03 mg/kg-
d for RBC AChE inhibition (U.S. EPA 2011).
Therefore, the most sensitive endpoint for CPF
is RBC AChE inhibition. Taking into consider-
ation consistency of outcomes across studies,
and strength of experimental design and meth-
ods for risk assessment purposes, the NOAEL
for behavioral effects is 1 mg/kg-d. There is
strong evidence from the animal literature that
AChE inhibition (RBC or brain from adult or
offspring) is a sensitive endpoint that is protec-
tive of neurobehavioral, neuropharmacologic,
and morphologic alterations that were mea-
sured following gestational, lactational, and/or
early postnatal exposures to 1 to 6 mg/kg-d.
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ACRONYMS
5HT serotonin
AChE acetylcholinesterase
ADHD attention deﬁcit hyperactivity disorder
AUC area under the curve
BMDL10 benchmark dose lower conﬁdence limit for 10% effect
BNBAS Brazelton Neonatal Behavioral Assessment Scale
BSID Bayley Scales of Infant Development II
BSID:MDI Bayley Scales of Infant Development II – Mental Development Index
(sometimes abbreviated to just MDI)
BSID:PDI Bayley Scales of Infant Development II – Psychomotor Development Index
(sometimes abbreviated to just PDI)
BuChE butyrylcholinesterase
CBCL child behavior checklist
CCCEH Columbia Center for Children’s Environmental Health
CHAMACOS Center for Health Assessment of Mothers and Children of Salina
ChAT choline acetyl transferase
ChE cholinesterase (used when referring to both AChE and BuChE)
CI conﬁdence interval
CPF chlorpyrifos
CPO chlorpyrifos-oxon
d day or days
DA Dopamine
DAPs total group of dialkylphosphates (includes DEPs and DMPs)
DEP diethylphosphate
DEPs total group of diethylphosphates (DEP , DETP , DEDTP)
DETP diethylthiophosphate
DEDTP diethyldithiophosphate
DMPs total group of dimethylphosphates
DMS-IV Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
DMSO dimethyl sulfoxide
EPA U.S. Environmental Protection Agency
GD gestational day
GFAP glial ﬁbrillary acidic protein
HAChT high afﬁnity presynaptic choline transporter
min minute or minutes
mAChR muscarinic cholinergic receptor
MDI mental development index (same as BSID:MDI)
mg milligram
NBAS Neonatal Behavioral Assessment Scale
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NOEL no-observed-effect-level
NOAEL no-observed-adverse-effect level
OP OP insecticides
OR odds ratio
PBPK physiologically based pharmacokinetic (model)
PDD pervasive development disorders
PDI psychomotor development index (same as BSID:PDI)
PND postnatal day
PON1 paraoxonase
RBC red blood cell
RR risk ratio
sc subcutaneous(ly)
SEM standard error of the mean
TCPy 3,5,6-trichloro-2-pyridionol
USV ultrasonic vocalizations
VAChT vesicular Ach transporter
µgm i c r o g r a m